Precigen (PGEN) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-36042
Entity Registrant Name	INTREXON CORPORATION
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	26-0084895
Entity Address, Address Line One	20374 Seneca Meadows Parkway
Entity Address, City or Town	Germantown,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20876
City Area Code	301
Local Phone Number	556-9900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	XON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		162,682,637
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001356090
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 44,428	$ 102,768
Restricted cash	0	6,987
Short-term investments	45,285	119,688
Equity securities	16,320	384
Receivables
Trade, net	20,413	21,195
Related parties, net	2,588	4,129
Other, net	1,970	2,754
Inventory	17,295	21,447
Prepaid expenses and other	9,033	6,131
Total current assets	157,332	285,483
Equity securities, noncurrent	6,515	1,798
Property, plant and equipment, net	122,706	128,874
Intangible assets, net	107,141	129,291
Goodwill	147,949	149,585
Investments in affiliates	17,487	18,859
Right-of-use assets	43,211	0
Other assets	2,564	2,287
Total assets	604,905	716,177
Current liabilities
Accounts payable	7,395	13,420
Accrued compensation and benefits	9,862	10,687
Other accrued liabilities	13,664	20,620
Deferred revenue, including $4,205 and $6,945 from related parties as of September 30, 2019 and December 31, 2018, respectively	12,764	15,554
Lines of credit	569	466
Current portion of long-term debt, including $30,974 to related parties as of September 30, 2019	31,433	559
Current portion of lease liabilities	6,224	0
Related party payables	44	256
Total current liabilities	81,955	61,562
Long-term debt, net of current portion, including $25,000 and $55,290 to related parties as of September 30, 2019 and December 31, 2018, respectively	184,034	211,235
Deferred revenue, net of current portion, including $51,900 and $52,227 from related parties as of September 30, 2019 and December 31, 2018, respectively	66,360	54,210
Lease liabilities, net of current portion	38,182	0
Deferred tax liabilities, net	5,732	7,213
Other long-term liabilities	221	3,235
Total liabilities	376,484	337,455
Commitments and contingencies (Note 16)
Total equity
Common stock, no par value, 400,000,000 and 200,000,000 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 162,511,940 and 160,020,466 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	0	0
Additional paid-in capital	1,745,177	1,722,012
Accumulated deficit	(1,483,654)	(1,330,545)
Accumulated other comprehensive loss	(33,102)	(28,612)
Total Intrexon shareholders' equity	228,421	362,855
Noncontrolling interests	0	15,867
Total equity	228,421	378,722
Total liabilities and total equity	$ 604,905	$ 716,177

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Current portion of deferred revenue	$ 12,764	$ 15,554
Long-term portion of deferred revenue	66,360	54,210
Current portion of long-term debt	31,433	559
Long-term debt, less current portion	$ 184,034	$ 211,235
Common stock, shares authorized (in shares)	400,000,000	200,000,000
Common stock, shares issued (in shares)	162,511,940	160,020,466
Common stock, shares outstanding (in shares)	162,511,940	160,020,466
Related Parties, Aggregated
Related Party Transaction [Line Items]
Current portion of deferred revenue	$ 4,205	$ 6,945
Long-term portion of deferred revenue	51,900	52,227
Current portion of long-term debt	30,974	0
Long-term debt, less current portion	$ 25,000	$ 55,290

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues
Revenues	$ 23,043	$ 32,448	$ 82,364	$ 117,389
Operating Expenses
Research and development	31,480	44,885	99,060	124,072
Selling, general and administrative	24,741	38,708	79,818	112,872
Impairment loss	626	0	626	0
Total operating expenses	71,660	98,919	227,093	286,117
Operating loss	(48,617)	(66,471)	(144,729)	(168,728)
Other Expense, Net
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net	(3,068)	(7,287)	2,634	(27,565)
Interest expense	(4,471)	(3,999)	(13,140)	(4,240)
Interest and dividend income	885	6,107	3,280	17,323
Other income, net	2,772	1,452	673	571
Total other expense, net	(3,882)	(3,727)	(6,553)	(13,911)
Equity in net loss of affiliates	(1,647)	(2,870)	(5,034)	(9,880)
Loss before income taxes	(54,146)	(73,068)	(156,316)	(192,519)
Income tax benefit	512	14,322	1,615	19,535
Net loss	(53,634)	(58,746)	(154,701)	(172,984)
Net loss attributable to the noncontrolling interests	0	1,422	1,592	4,113
Net loss attributable to Intrexon	$ (53,634)	$ (57,324)	$ (153,109)	$ (168,871)
Net loss attributable to Intrexon per share, basic and diluted (in usd per share)	$ (0.35)	$ (0.44)	$ (1)	$ (1.31)
Weighted average shares outstanding, basic and diluted (in shares)	154,596,257	129,518,989	153,770,785	128,843,991
Collaboration and licensing agreements
Revenues
Revenues	$ 6,185	$ 14,324	$ 21,252	$ 51,622
Products
Revenues
Revenues	5,852	6,829	18,528	23,549
Operating Expenses
Cost of products and services	8,263	8,877	25,729	28,046
Services
Revenues
Revenues	9,924	10,414	39,707	40,379
Operating Expenses
Cost of products and services	6,550	6,449	21,860	21,127
Other
Revenues
Revenues	$ 1,082	$ 881	$ 2,877	$ 1,839

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Related Party Transaction [Line Items]
Revenues	$ 23,043	$ 32,448	$ 82,364	$ 117,389
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	6,185	14,324	21,252	51,622
Collaboration and licensing agreements | Related Parties, Aggregated
Related Party Transaction [Line Items]
Revenues	$ 3,428	$ 11,952	$ 14,350	$ 41,740

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (53,634)	$ (58,746)	$ (154,701)	$ (172,984)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(25)	(96)	81	(94)
Loss on foreign currency translation adjustments	(4,871)	(914)	(4,560)	(7,207)
Comprehensive loss	(58,530)	(59,756)	(159,180)	(180,285)
Comprehensive loss attributable to the noncontrolling interests	0	1,380	1,581	4,172
Comprehensive loss attributable to Intrexon	$ (58,530)	$ (58,376)	$ (157,599)	$ (176,113)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' and Total Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Intrexon Shareholders' Equity	Noncontrolling Interests
Balances (in shares) at Dec. 31, 2017		122,087,040
Balances at Dec. 31, 2017	$ 546,545	$ 0	$ 1,397,005	$ (15,554)	$ (847,820)	$ 533,631	$ 12,914
Increase (Decrease) in Stockholders' Equity
Cumulative effect of adoption of new accounting pronouncements	26,507			(104)	26,611	26,507
Stock-based compensation expense	28,340		28,251			28,251	89
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares)		66,314
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	1,074		262			262	812
Shares issued as payment for services (in shares)		612,117
Shares issued as payment for services	8,404		8,404			8,404	0
Equity component of convertible debt, net of issuance costs and deferred taxes	$ 36,868		36,868			36,868
Shares issued pursuant to share lending agreement (in shares)	7,479,431
Shares and warrants issued in public offerings, net of issuance costs (in shares)		6,900,000
Shares and warrants issued in public offerings, net of issuance costs	$ 87,990		82,374			82,374	5,616
Adjustments for noncontrolling interests	0		(785)			(785)	785
Net loss	(172,984)				(168,871)	(168,871)	(4,113)
Other comprehensive income (loss)	(7,301)			(7,242)		(7,242)	(59)
Balances (in shares) at Sep. 30, 2018		137,144,902
Balances at Sep. 30, 2018	555,443	$ 0	1,552,379	(22,900)	(990,080)	539,399	16,044
Balances (in shares) at Jun. 30, 2018		129,421,788
Balances at Jun. 30, 2018	567,141	$ 0	1,504,356	(21,848)	(932,756)	549,752	17,389
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	8,132		8,097			8,097	35
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares)		39,281
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	141		141			141	0
Shares issued as payment for services (in shares)		204,402
Shares issued as payment for services	2,917		2,917			2,917
Equity component of convertible debt, net of issuance costs and deferred taxes	36,868		36,868			36,868
Shares issued pursuant to share lending agreement (in shares)		7,479,431
Net loss	(58,746)				(57,324)	(57,324)	(1,422)
Other comprehensive income (loss)	(1,010)			(1,052)		(1,052)	42
Balances (in shares) at Sep. 30, 2018		137,144,902
Balances at Sep. 30, 2018	$ 555,443	$ 0	1,552,379	(22,900)	(990,080)	539,399	16,044
Balances (in shares) at Dec. 31, 2018	160,020,466	160,020,466
Balances at Dec. 31, 2018	$ 378,722	$ 0	1,722,012	(28,612)	(1,330,545)	362,855	15,867
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	14,538		14,469			14,469	69
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares)		796,859
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	313		63			63	250
Shares issued for accrued compensation (in shares)		150,908
Shares issued for accrued compensation	1,102		1,102			1,102
Shares issued as payment for services (in shares)		1,543,707
Shares issued as payment for services	7,987		7,987			7,987
Shares and warrants issued in public offerings, net of issuance costs	6,611						6,611
Adjustments for noncontrolling interests	0		(456)			(456)	456
Deconsolidation of subsidiary	(21,672)						(21,672)
Net loss	(154,701)				(153,109)	(153,109)	(1,592)
Other comprehensive income (loss)	$ (4,479)			(4,490)		(4,490)	11
Balances (in shares) at Sep. 30, 2019	162,511,940	162,511,940
Balances at Sep. 30, 2019	$ 228,421	$ 0	1,745,177	(33,102)	(1,483,654)	228,421	0
Balances (in shares) at Jun. 30, 2019		161,917,424
Balances at Jun. 30, 2019	279,223	$ 0	1,737,449	(28,206)	(1,430,020)	279,223	0
Increase (Decrease) in Stockholders' Equity
Stock-based compensation expense	5,423		5,423			5,423	0
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares)		164,844
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	6		6			6	0
Shares issued as payment for services (in shares)		429,672
Shares issued as payment for services	2,299		2,299			2,299
Net loss	(53,634)				(53,634)	(53,634)	0
Other comprehensive income (loss)	$ (4,896)			(4,896)		(4,896)	0
Balances (in shares) at Sep. 30, 2019	162,511,940	162,511,940
Balances at Sep. 30, 2019	$ 228,421	$ 0	$ 1,745,177	$ (33,102)	$ (1,483,654)	$ 228,421	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (154,701)	$ (172,984)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,711	25,184
Loss on disposals of assets, net	1,875	4,110
Impairment loss	626	0
Write-off of in-process research and development acquired in asset acquisition	0	8,721
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net	(2,634)	27,565
Noncash dividend income	(38)	(14,575)
Amortization of discounts on investments, net	(949)	(275)
Equity in net loss of affiliates	5,034	9,880
Stock-based compensation expense	14,538	28,340
Shares issued as payment for services	7,987	8,404
Provision for bad debts	787	1,597
Accretion of debt discount and amortization of deferred financing costs	6,962	2,116
Deferred income taxes	(1,448)	(19,335)
Other noncash items	3,284	635
Receivables:
Trade	241	399
Related parties	1,190	6,085
Other	462	(909)
Inventory	4,775	2,577
Prepaid expenses and other	(4,320)	(511)
Right-of-use assets	2,593	0
Other assets	(41)	584
Accounts payable	(4,432)	(731)
Accrued compensation and benefits	535	17,561
Other accrued liabilities	(5,651)	1,591
Deferred revenue	5,056	(22,993)
Lease liabilities	(3,680)	0
Related party payables	38	(167)
Other long-term liabilities	(585)	253
Net cash used in operating activities	(103,785)	(86,878)
Cash flows from investing activities
Purchases of investments	(55,073)	(178,681)
Sales of investments	2,996	0
Maturities of investments	127,500	20,975
Proceeds from sales of equity securities	589	217
Investments in affiliates	(3,713)	(14,139)
Decrease in cash from deconsolidation of subsidiary	(7,244)	0
Return of investment in affiliate	125	2,598
Cash received in asset acquisition	0	15,500
Purchases of property, plant and equipment	(33,199)	(30,354)
Proceeds from sale of assets	361	1,930
Net cash provided by (used in) investing activities	32,342	(181,954)
Cash flows from financing activities
Proceeds from issuance of shares and warrants in public offerings, net of issuance costs	6,611	87,990
Advances from lines of credit	4,623	3,231
Repayments of advances from lines of credit	(4,520)	(3,264)
Proceeds from long-term debt, net of issuance costs	376	194,000
Payments of long-term debt	(464)	(485)
Proceeds from stock option and warrant exercises	313	1,074
Net cash provided by financing activities	6,939	282,546
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(843)	578
Net increase (decrease) in cash, cash equivalents, and restricted cash	(65,347)	14,292
Cash, cash equivalents, and restricted cash
Beginning of period	110,182	75,545
End of period	44,835	89,837
Supplemental disclosure of cash flow information
Cash paid during the period for interest	3,698	360
Cash paid during the period for income taxes	50	193
Significant noncash financing and investing activities
Stock received as consideration for collaboration agreements	4,530	0
Long-term debt issued to a related party in an asset acquisition	0	30,000
Purchases of property and equipment included in accounts payable and other accrued liabilities	692	2,088
Purchases of equipment financed through debt	$ 0	$ 193

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 44,428	$ 102,768
Restricted cash	0	6,987
Restricted cash included in other assets	407	427
Cash, cash equivalents, and restricted cash	$ 44,835	$ 110,182

Organization

Organization	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Intrexon Corporation ("Intrexon"), a Virginia corporation, uses synthetic biology to focus on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals, which may be accomplished directly or through collaborations and joint ventures. Intrexon's primary domestic operations are in Florida, Maryland, and Virginia, and its primary international operations are in Hungary. There have been no commercialized products derived either directly by Intrexon or through its collaborations or joint ventures to date. Precigen, Inc. ("Precigen"), a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases, is a wholly owned subsidiary of Intrexon with primary operations in Maryland. Effective October 1, 2019, Intrexon transferred substantially all of its proprietary methane bioconversion platform assets to a new wholly owned subsidiary, MBP Titan LLC ("MBP"). MBP's proprietary methane bioconversion platform is designed to turn natural gas into more valuable and usable energy and chemical products via microbial fermentation. The operations of MBP are primarily in California. Prior to October 1, 2019, MBP was an operating division within Intrexon. There were no accounting implications resulting from the transfer of these assets. ActoBio Therapeutics, Inc. ("ActoBio") is pioneering a new class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Intrexon with primary operations in Belgium. Trans Ova Genetics, L.C. ("Trans Ova"), Progentus, L.C. ("Progentus"), and ViaGen, L.C. ("ViaGen"), providers of advanced reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in California, Iowa, Maryland, Missouri, New York, Oklahoma, Texas, and Washington. Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in Brazil and the United Kingdom. Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan Specialty Fruits"), a company that developed and received regulatory approval for the world's first non-browning apple without the use of any artificial additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington. IPHI and its subsidiaries are hereinafter referred to as "Okanagan." Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, is a wholly owned subsidiary with primary operations in Iowa. Through April 8, 2019, Intrexon consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Intrexon no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Intrexon deconsolidated AquaBounty. After remeasuring its retained interest in AquaBounty, Intrexon recorded a loss on deconsolidation of $2,648 , which is included in other income, net, on the accompanying consolidated statement of operations for the nine months ended September 30, 2019 . The deconsolidation resulted in the derecognition of the carrying amount of $38,682 in net assets that are no longer reported in the accompanying consolidated balance sheet as of September 30, 2019 . See Notes 9 , 10 , and 11 for additional discussion of material impacts to the accompanying consolidated balance sheet as of September 30, 2019 . As of September 30, 2019 , Intrexon owned approximately 38% of AquaBounty and, after deconsolidating the entity, accounts for these equity securities using the fair value option. See Notes 2 and 20 for additional discussion of Intrexon's investment in AquaBounty. Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company."

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2019 and results of operations and cash flows for the interim periods ended September 30, 2019 and 2018 . The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2019 , or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 . The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated. Liquidity and Going Concern The Company has incurred operating losses since its inception and management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. As of September 30, 2019 , the Company had $89,713 in cash, cash equivalents and short-term investments which is not sufficient to fund the Company's planned operations through one year after the date the interim unaudited consolidated financial statements are issued, and accordingly, there is substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern does not include cash sources outside of the Company's direct control that could be available within the next twelve months. Management plans to obtain sufficient additional funding through monetizing certain of its existing assets, entering into new license and collaboration agreements, issuing additional equity or debt instruments or any other means, and if it is able to do so, they may not be on satisfactory terms. The Company's ability to raise additional capital in the equity and debt markets, should the Company choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Should the Company not be able to secure additional funding through these means, the Company may have to engage in any or all of the following activities: (i) shift the Company's internal investments from subsidiaries and platforms whose potential for value creation is longer-term to near-term opportunities; (ii) sell certain of our operating subsidiaries, or portions thereof, to third parties; (iii) reduce operating expenditures for third-party contractors, including consultants, professional advisors, and other vendors; and (iv) reduce or delay capital expenditures, including facility expansions, lab equipment, and information technology projects. These actions may have a material adverse impact on the Company's ability to achieve certain of its planned objectives. Even if the Company is able to source additional funding, it may be forced to significantly reduce its operations if its business prospects do not improve. If the Company is unable to source additional funding, it may be forced to shut down operations altogether. These interim unaudited consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event the Company can no longer continue as a going concern. Equity Securities The Company holds equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluates whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statements of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represents cost and any adjustments for impairment or observable price changes in certain transactions. As of September 30, 2019 , there have been no adjustments for impairment or observable price changes for the Company's investments in private companies accounted for under the measurement alternative method. Equity securities that the Company does not intend to sell within one year are classified as noncurrent in the consolidated balance sheets. For equity securities received pursuant to a collaboration agreement, the Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter. Equity Method Investments The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Note 3 and to certain of the Company's joint ventures in Note 4 . Effective in April 2019, the Company accounts for its investment in AquaBounty, a related party, using the fair value option. The fair value of the Company's investment in AquaBounty was $16,320 as of September 30, 2019 and is included in equity securities in the accompanying consolidated balance sheet. The Company's ownership of AquaBounty was approximately 38% as of September 30, 2019 . Unrealized appreciation (depreciation) in the fair value of the Company's investment in AquaBounty common stock was $(3,721) and $2,081 for the three and nine months ended September 30, 2019 , respectively. See Notes 1 and 20 for additional discussion regarding AquaBounty. The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators and a related party, using the fair value option. Oragenics was considered an equity method investment through September 30, 2018. See Note 17 for additional discussion regarding Oragenics. Unrealized depreciation in the fair value of the Company's investment in Oragenics common stock was $(387) and $(1,547) for the three and nine months ended September 30, 2018 , respectively. Summarized financial data as of September 30, 2019 and December 31, 2018 and for the three and nine months ended September 30, 2019 and 2018 , for the Company's equity method investments are shown in the following tables. September 30, December 31, Current assets $ 16,983 $ 17,485 Noncurrent assets 59,231 31,274 Total assets 76,214 48,759 Current liabilities 6,788 4,226 Noncurrent liabilities 4,766 — Total liabilities 11,554 4,226 Net assets $ 64,660 $ 44,533 Three Months Ended Nine Months Ended 2019 2018 2019 2018 Revenues $ 206 $ 113 $ 601 $ 353 Operating expenses 6,843 11,621 21,604 30,762 Operating loss (6,637 ) (11,508 ) (21,003 ) (30,409 ) Other, net 1 12 9 33 Net loss $ (6,636 ) $ (11,496 ) $ (20,994 ) $ (30,376 ) Variable Interest Entities As of September 30, 2019 and December 31, 2018 , the Company determined that certain of its collaborators and joint ventures, as well as Harvest, were variable interest entities ("VIE" or "VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of September 30, 2019 and December 31, 2018 were $20,453 and $21,219 , respectively, which represents the Company's maximum risk of loss related to the identified VIEs. Operating Leases The Company adopted Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"), effective January 1, 2019. Under ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, with an ROU Asset of the same amount. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Segment Information The Company realigned its business in April 2019, and as a result, its chief operating decision maker ("CODM") now regularly reviews disaggregated financial information for various operating segments. The Company's reportable segments now include (i) Precigen; (ii) MBP; (iii) the Fine Chemicals division, which is an operating division of Intrexon; (iv) Okanagan; and (v) Trans Ova. All of Intrexon's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of Precigen, MBP, Okanagan, and Trans Ova. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to multiple reportable segments. See Note 19 for further discussion of the Company's segments. Recently Adopted Accounting Pronouncements The Company adopted ASC 842 on January 1, 2019 using the modified retrospective method as of the adoption date without restating prior periods. In addition, the Company elected to use the package of practical expedients which allowed the Company to not have to reassess whether expired or existing contracts contain leases under the new definition of a lease or the lease classification for expired or existing leases under ASC Topic 840. As a result of the adoption of ASC 842, the Company recorded ROU Assets and lease liabilities of approximately $43,500 and $45,500 , respectively, as of January 1, 2019. The difference between the ROU Assets and lease liabilities primarily represents the balance of deferred rent as of December 31, 2018 that resulted from historical straight-lining of operating leases expense, which was reclassified upon adoption to reduce the measurement of the ROU Assets. There was no impact to accumulated deficit. In June 2018, the FASB issued Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The provisions of ASU 2018-07 expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this standard effective January 1, 2019, and there was no material impact to the accompanying consolidated financial statements. Recently Issued Accounting Pronouncements In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified or removed. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, but entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. This standard is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13") . The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). The provisions of ASU 2019-04 clarify and improve areas of guidance related to ASU 2016-13 and ASC Topic 825, Financial Instruments ("ASC 825"). The amendments to ASU 2016-13 have the same effective date as the original ASU and are effective for the Company for the year ending December 31, 2020. The amendments to ASC 825 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted, and are effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

Mergers and Acquisitions

Mergers and Acquisitions	9 Months Ended
	Sep. 30, 2019
Mergers and Acquisitions [Abstract]
Mergers and Acquisitions	Mergers and Acquisitions Asset Acquisition of Certain Harvest Entities In September 2018, the Company, through its wholly owned subsidiary ActoBio, issued $30,000 of convertible promissory notes to Harvest, a related party, to acquire Harvest's ownership in CRS Bio, Inc., Genten Therapeutics, Inc., and Relieve Genetics, Inc. (collectively the "Harvest entities"). The Company also received $15,500 cash in the transaction from the acquisition of the Harvest entities. Prior to the transaction, the Company held a noncontrolling interest in the Harvest entities, with a combined carrying value for all entities of $4,303 , and accounted for its ownership using the equity method of accounting. Following the transaction, the Company owns 100% of the equity interests of the Harvest entities including the rights that had been previously licensed to the Harvest entities by the Company. The Harvest entities did not meet the definition of a business and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to the Harvest entities, the Company was relieved from its obligations under the original exclusive channel collaborations ("ECCs") and therefore wrote off deferred revenue of $10,078 in September 2018 as part of the transaction. The remaining value acquired of $8,721 was considered in-process research and development related to the reacquired rights under the ECCs and expensed immediately. See Note 11 for additional discussion of the convertible promissory notes.

Investments in Joint Ventures

Investments in Joint Ventures	9 Months Ended
	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's methane bioconversion platform technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50% . In addition, Intrexon has committed to make capital contributions of up to $25,000 , and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000 , at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of September 30, 2019 , the Company's remaining commitment was $4,225 . Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(355) and $(656) as of September 30, 2019 and December 31, 2018 , respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's methane bioconversion platform technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50% . In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000 , half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000 , and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000 , at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(425) and $(50) as of September 30, 2019 and December 31, 2018 , respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets. EnviroFlight In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products, from black soldier fly larvae. Through September 30, 2019 , the Company and Darling have made subsequent capital contributions of $19,000 each. The Company's investment in New EnviroFlight was $15,629 and $16,720 as of September 30, 2019 and December 31, 2018 , respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets. Intrexon T1D Partners In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners that provided the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50% . Intrexon committed to make capital contributions of up to $5,000 , and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, committed to make additional capital contributions of up to $5,000 , at the request of Intrexon T1D Partners' board of managers, which consisted of two members appointed by the Company and three members appointed by a majority of the T1D Investors. The Company satisfied its commitment in 2018. In November 2018, the Company, together with its wholly owned subsidiary ActoBio, issued 1,933,737 shares of Intrexon common stock valued at $18,970 to the T1D Investors to acquire their ownership interest in Intrexon T1D Partners. Following the transaction, the Company owns 100% of the membership interests in Intrexon T1D Partners, including the rights that had been previously licensed to Intrexon T1D Partners by the Company in the ECC. Intrexon T1D Partners did not meet the definition of a business, and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to Intrexon T1D Partners, the Company was relieved from its obligations under the original ECC and therefore wrote off $8,517 of deferred revenue in November 2018 as part of the transaction. The remaining value of $10,453 was considered in-process research and development related to the reacquired rights under the ECC and expensed immediately.

Collaboration and Licensing Rev

Collaboration and Licensing Revenue	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration and Licensing Revenue	Collaboration and Licensing Revenue The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. At contract inception, the transaction price is typically the upfront payment received and is allocated to the single performance obligation. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed. At the inception of each collaboration, the Company determines whether any milestone payments are probable and can be included in the transaction price. The milestone payments are typically not considered probable at inception and are therefore constrained. Royalties related to product sales will be recognized when sales have occurred since the royalties relate directly to the technology license granted in the agreement. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2019 and 2018 . Three Months Ended Nine Months Ended 2019 2018 2019 2018 ZIOPHARM Oncology, Inc. $ 431 $ 4,826 $ 2,130 $ 13,626 Ares Trading S.A. — 1,576 — 7,525 Oragenics, Inc. 231 705 615 867 Intrexon T1D Partners, LLC — 368 — 2,399 Intrexon Energy Partners, LLC 823 1,329 2,596 3,345 Intrexon Energy Partners II, LLC 293 754 1,217 1,685 Surterra Holdings, Inc. 1,022 — 1,182 — Genopaver, LLC 494 689 1,186 3,076 Fibrocell Science, Inc. 402 391 3,247 1,015 Persea Bio, LLC 1,083 199 621 714 Harvest start-up entities (1) 100 2,691 4,862 11,792 Other 1,306 796 3,596 5,578 Total $ 6,185 $ 14,324 $ 21,252 $ 51,622 (1) For the three and nine months ended September 30, 2019 and 2018 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the nine months ended September 30, 2018 , revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc. Except for the agreements discussed below, there have been no significant changes to the agreements with our collaborators and licensees in the nine months ended September 30, 2019 . Surterra Collaboration In June 2019, the Company entered into an Exclusive Product Collaboration agreement ("Surterra EPC") with Surterra Holdings, Inc. ("Surterra") to advance Surterra's cannabinoid production at a reliable, efficient, cost-effective, and industrial scale utilizing the Company's yeast fermentation platform. Under the Surterra EPC, Surterra is responsible for the commercialization of products, including securing any regulatory approvals. Upon execution of the Surterra EPC, the Company received a technology access fee in the form of a $10,000 cash payment and common stock of Surterra valued at $4,530 as upfront consideration. The Company is entitled to developmental milestones for each target selected by Surterra up to a maximum of $68,000 for the achievement of all milestones for all targets as defined in the agreement. The Company is entitled to payments for research and development services provided pursuant to the agreement as well as single-digit royalties on quarterly gross sales of products developed. The Company's performance obligations terminate upon the acceptance of all deliverables for each target selected under the agreement, and the agreement may be terminated by either party in the event of a material breach as defined in the agreement or may be terminated voluntarily by Surterra upon 90 days written notice to the Company. Fibrocell Science Collaboration In April 2019, Fibrocell Science, Inc. ("Fibrocell"), a publicly traded cell and gene therapy company focused on disease affecting the skin and connective tissue and a related party, entered into a collaboration agreement with a third party to develop and commercialize a product in the field of the Company's ECC with Fibrocell ("Fibrocell ECC"). Pursuant to the terms of the Fibrocell ECC, the Company is entitled to 50% of sublicensing fees and received $3,750 during the nine months ended September 30, 2019 . Deferred Revenue Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consists of the following: September 30, December 31, Collaboration and licensing agreements $ 74,431 $ 63,284 Prepaid product and service revenues 3,054 2,933 Other 1,639 3,547 Total $ 79,124 $ 69,764 Current portion of deferred revenue $ 12,764 $ 15,554 Long-term portion of deferred revenue 66,360 54,210 Total $ 79,124 $ 69,764 The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2019 and December 31, 2018 , including the estimated remaining performance period as of September 30, 2019 . Average Remaining Performance Period (Years) September 30, December 31, ZIOPHARM Oncology, Inc. 0.0 $ — $ 1,214 Oragenics, Inc. 4.7 5,463 5,810 Intrexon Energy Partners, LLC 4.5 8,362 10,267 Intrexon Energy Partners II, LLC 5.2 12,843 14,060 Surterra Holdings, Inc. 8.7 13,987 — Genopaver, LLC 4.5 789 1,175 Fibrocell Science, Inc. 5.1 18,102 17,519 Persea Bio, LLC 5.3 3,553 2,697 Harvest start-up entities (1) 5.4 6,993 7,644 Other 1.7 4,297 2,898 Total $ 74,389 $ 63,284 (1) As of September 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Short-term Investments

Short-term Investments	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	Short-term Investments The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of September 30, 2019 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 44,925 $ 20 $ — $ 44,945 Certificates of deposit 340 — — 340 Total $ 45,265 $ 20 $ — $ 45,285 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 119,401 $ — $ (61 ) $ 119,340 Certificates of deposit 348 — — 348 Total $ 119,749 $ — $ (61 ) $ 119,688 As of September 30, 2019 , all of the available-for-sale investments were due within one year based on their contractual maturities. Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments, and there were no unrealized losses as of September 30, 2019 . As of September 30, 2019 and December 31, 2018 , the Company did not consider any of its debt security investments to be other-than-temporarily impaired. When evaluating its debt security investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amount of cash and cash equivalents, restricted cash, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments. Assets The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at September 30, 2019 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, Assets U.S. government debt securities $ — $ 44,945 $ — $ 44,945 Equity securities 1,687 298 16,320 18,305 Other — 593 390 983 Total $ 1,687 $ 45,836 $ 16,710 $ 64,233 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2018 : Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 119,340 $ — $ 119,340 Equity securities 1,626 556 — 2,182 Other — 468 191 659 Total $ 1,626 $ 120,364 $ 191 $ 122,181 The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The methods used to estimate the fair value of the Level 2 and Level 3 equity securities in the tables above are based on the quoted market price of the publicly-traded security, adjusted for any trading restrictions, including discounts for lack of marketability based on historical volatilities and the restriction period. Market price volatility of these Level 3 securities and a significant change in the assumptions used in the discount for lack of marketability could result in a significant impact to the fair value. The Company owns preferred stock in certain of its collaborators, and these investments are classified as Level 3 within the fair value hierarchy. The methods used to estimate the fair value of these Level 3 assets are discussed in Note 17 . The following table summarizes the changes in the Level 3 investments in equity securities and preferred stock during the nine months ended September 30, 2019 . Nine Months Ended Beginning balance $ 191 Retained interest in deconsolidated subsidiary 14,239 Dividend income from investments in preferred stock 38 Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock 2,242 Ending balance $ 16,710 There were no transfers of assets between levels of the fair value hierarchy during the nine months ended September 30, 2019 . Liabilities The carrying values of the Company's long-term debt, excluding the 3.50% convertible senior notes due 2023 (the "Convertible Notes"), approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The calculated fair value of the Convertible Notes (Note 11 ) was approximately $122,000 and $141,000 as of September 30, 2019 and December 31, 2018 , respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $155,063 and $148,101 as of September 30, 2019 and December 31, 2018 , respectively. The Company's contingent consideration liabilities are measured on a recurring basis and were $585 at September 30, 2019 and December 31, 2018 . These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. There were no changes in the fair value of the Level 3 liabilities during the nine months ended September 30, 2019 .

Inventory

Inventory	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: September 30, December 31, Supplies, embryos and other production materials $ 3,461 $ 4,729 Work in process 4,656 4,391 Livestock 6,505 10,167 Feed 2,673 2,160 Total inventory $ 17,295 $ 21,447

Property, Plant and Equipment,

Property, Plant and Equipment, Net	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment consist of the following: September 30, December 31, Land and land improvements $ 11,011 $ 12,490 Buildings and building improvements 11,607 20,371 Furniture and fixtures 1,388 1,891 Equipment 67,020 74,555 Leasehold improvements 30,722 28,289 Breeding stock 4,867 4,582 Computer hardware and software 11,385 11,697 Trees 16,728 11,910 Construction and other assets in progress 26,319 18,880 181,047 184,665 Less: Accumulated depreciation and amortization (58,341 ) (55,791 ) Property, plant and equipment, net $ 122,706 $ 128,874 The deconsolidation of AquaBounty (Note 1 ) in April 2019 resulted in the reduction of $24,186 of property, plant and equipment, net on the accompanying consolidated balance sheet as of September 30, 2019 . During the three and nine months ended September 30, 2019 , the Company recorded $448 of property, plant and equipment impairment losses in conjunction with the closing of two of its reporting units during the third quarter of 2019. During the three and nine months ended September 30, 2018, the Company recorded losses of $85 and $5,057 , respectively, on disposal of certain leasehold improvements, equipment, and other fixed assets, in conjunction with the closing of one of its research and development facilities in Brazil. Depreciation expense was $3,293 and $3,614 for the three months ended September 30, 2019 and 2018 , respectively, and $10,213 and $10,712 for the nine months ended September 30, 2019 and 2018 , respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for the nine months ended September 30, 2019 are as follows: Balance at December 31, 2018 $ 149,585 Impairment (178 ) Foreign currency translation adjustments (1,458 ) Balance at September 30, 2019 $ 147,949 The Company had $14,001 and $13,823 of accumulated impairment losses as of September 30, 2019 and December 31, 2018 , respectively. In April 2019, as a result of the Company's change in segments (Notes 2 and 19 ), the Company concluded that certain operating segments are now separate reporting units. Accordingly, the Company performed a relative fair value allocation of certain of its goodwill. During the three and nine months ended September 30, 2019 , the Company recorded $178 of goodwill impairment losses in conjunction with the closing of two of its reporting units during the third quarter of 2019. Intangible assets consist of the following as of September 30, 2019 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 136,114 $ (38,804 ) $ 97,310 Customer relationships 10,700 (8,221 ) 2,479 Trademarks 5,900 (3,685 ) 2,215 In-process research and development 5,137 — 5,137 Total $ 157,851 $ (50,710 ) $ 107,141 Intangible assets consist of the following as of December 31, 2018 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 152,482 $ (35,133 ) $ 117,349 Customer relationships 10,700 (7,565 ) 3,135 Trademarks 6,800 (3,341 ) 3,459 In-process research and development 5,348 — 5,348 Total $ 175,330 $ (46,039 ) $ 129,291 The balance of in-process research and development includes certain in-process research and development technology acquired in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have been obtained for the in-process programs. The deconsolidation of AquaBounty (Note 1 ) in April 2019 resulted in the reduction of $11,567 of net intangible assets, primarily related to patents, developed technologies, and know-how, on the accompanying consolidated balance sheet as of September 30, 2019 . Amortization expense was $2,728 and $4,689 for the three months ended September 30, 2019 and 2018 , respectively, and $8,498 and $14,472 for the nine months ended September 30, 2019 and 2018 , respectively.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Lines of Credit and Long-Term Debt	Lines of Credit and Long-Term Debt Lines of Credit Trans Ova has an $8,000 revolving line of credit with First National Bank of Omaha that matures on December 31, 2019. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% , and the actual rate was 5.06% as of September 30, 2019 . As of September 30, 2019 , there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount and was $7,930 as of September 30, 2019 . The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of September 30, 2019 . Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2020. As of September 30, 2019, the line of credit bore interest at 5.75% per annum, and there was an outstanding balance of $569 . Long-Term Debt Long-term debt consists of the following: September 30, December 31, Convertible debt $ 211,037 $ 203,391 Notes payable 4,204 4,551 Other 226 3,852 Long-term debt 215,467 211,794 Less current portion 31,433 559 Long-term debt, less current portion $ 184,034 $ 211,235 The deconsolidation of AquaBounty (Note 1 ) in April 2019 resulted in the reduction of $4,030 of long-term debt on the accompanying consolidated balance sheet as of September 30, 2019 . Convertible Debt Intrexon Convertible Notes In July 2018, Intrexon completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Intrexon and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Intrexon received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042 . The Convertible Notes are senior unsecured obligations of Intrexon and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023, unless earlier repurchased or converted. The Convertible Notes are convertible into cash, shares of Intrexon's common stock or a combination of cash and shares, at Intrexon's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Intrexon common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Intrexon will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances: • During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Intrexon's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Intrexon's common stock and the conversion rate for the Convertible Notes on each such trading day; or • Upon the occurrence of specified corporate events as defined in the Indenture. None of the above events allowing for conversion prior to April 1, 2023 occurred during the three months ended September 30, 2019 . On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Intrexon may not redeem the Convertible Notes prior to the maturity date. If Intrexon undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Intrexon to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Intrexon shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Intrexon's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture. The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723 , and additional paid-in capital, the equity component, in the amount of $50,235 . Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount. As of September 30, 2019 , the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $155,063 . The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02% . As of September 30, 2019 , the unamortized long-term debt discount and debt issuance costs totaled $44,937 . The components of interest expense related to the Convertible Notes were as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Cash interest expense $ 1,750 $ 1,731 $ 5,250 $ 1,731 Non-cash interest expense 2,430 2,116 6,962 2,116 Total interest expense $ 4,180 $ 3,847 $ 12,212 $ 3,847 Accrued interest of $1,750 is included in other accrued liabilities on the accompanying consolidated balance sheet as of September 30, 2019 . ActoBio Convertible Notes In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest (Note 3 ). The ActoBio Notes have a maturity date of September 6, 2020, accrue interest at 3.0% compounded annually, are convertible into shares of ActoBio common stock at any time by the holder, and are automatically convertible in shares of ActoBio common stock upon the closing of certain financing events as defined in the ActoBio Notes. If the ActoBio Notes have not been converted to ActoBio common stock by the maturity date, ActoBio can pay the principal and accrued interest in cash or with shares of Intrexon common stock at its election. There are no embedded features that are required to be separated from the debt host and accounted for separately, so the ActoBio Notes were recorded at $30,000 . Interest expense was $232 and $60 for the three months ended September 30, 2019 and 2018 , respectively, and $684 and $60 for the nine months ended September 30, 2019 and 2018 , respectively. As of September 30, 2019 , the carrying value of the ActoBio Notes, including accrued interest, was $30,974 . Intrexon and Precigen Convertible Note In December 2018, in conjunction with the Securities Purchase, Assignment and Assumption Agreement with Ares Trading S.A. ("Ares Trading"), Intrexon and Precigen jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note has a maturity date of June 28, 2021 and will be converted to Intrexon common stock on the first trading day following maturity if not otherwise converted prior to that date. Prior to maturity, Ares Trading may convert the Merck Note, at their election, into (i) Intrexon common stock at any time, (ii) Intrexon common stock upon the Company's closing of qualified financing as defined in the agreement, (iii) Precigen equity upon Precigen closing a qualified financing as defined in the agreement, and (iv) Precigen common stock upon the closing of a qualified initial public offering ("IPO") of Precigen common stock. In the event of a conversion upon a qualified IPO, the conversion price will be 90% of the IPO price. In the event Ares Trading elects to convert the Merck Note into Precigen equity, the Merck Note accrues interest at a rate of 5% per year ("PIK interest") and will be converted with the outstanding principal. The Company determined that the potential PIK interest and IPO conversion discount represented embedded derivatives requiring bifurcation from the debt host but had no significant value as of September 30, 2019 and December 31, 2018 . Notes Payable Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $4,180 as of September 30, 2019 . Trans Ova pays monthly installments of $39 , which includes interest at 3.95% . The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets. Future Maturities Future maturities of long-term debt are as follows: 2019 $ 127 2020 31,487 2021 25,330 2022 340 2023 200,354 2024 367 Thereafter 2,399 Total $ 260,404

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three and nine months ended September 30, 2019 , the Company had U.S. taxable loss of approximately $47,100 and $194,400 , respectively. For the three and nine months ended September 30, 2019 , the Company recognized $45 and $167 , respectively, of current foreign income tax benefit. For the three and nine months ended September 30, 2018 , the Company had U.S. taxable loss of approximately $39,100 and $104,400 , respectively, and recorded $31 of current domestic income tax benefit and $82 of current domestic income tax expense, respectively. For the three and nine months ended September 30, 2018 , the Company recognized $45 and $282 , respectively, of current foreign income tax benefit. For the three and nine months ended September 30, 2019 , the Company recorded deferred tax benefit of $467 and $1,448 , respectively. For the three and nine months ended September 30, 2018 , the Company recorded deferred tax benefit of $14,246 and $19,335 , respectively. Of these amounts, $13,367 relates to deferred tax benefits recognized from the reversal of valuation allowances on current year domestic operating losses in the same amount as the deferred taxes recorded as a direct reduction of additional paid-in capital related to the issuance of the Convertible Notes (Note 11 ). The Company considered amounts recorded directly to shareholders' equity in evaluating the need for a valuation allowance on deferred tax assets related to continuing operations. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $5,732 , are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. As of September 30, 2019 , the Company has operating and capital loss carryforwards for U.S. federal income tax purposes of approximately $564,100 available to offset future taxable income, including approximately $311,400 generated after 2017, and federal and state research and development tax credits of approximately $9,200 , prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended. Carryforwards generated prior to 2018 begin to expire in 2022. As of September 30, 2019 , the Company's foreign subsidiaries have foreign loss carryforwards of approximately $159,200 , most of which do not expire.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Issuances of Intrexon Common Stock In January 2018, Intrexon closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374 , after deducting underwriting discounts of $3,688 and offering expenses of $188 , all of which were capitalized. Share Lending Agreement Concurrently with the offering of the Convertible Notes (Note 11 ), Intrexon entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Intrexon loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Intrexon within five business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Intrexon did not receive any proceeds from the sale of the Borrowed Shares to the public. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering. The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Intrexon shareholders unless the Share Borrower defaults on the Share Lending Agreement. Issuances of AquaBounty Common Stock In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $6,611 after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty. In January 2018, AquaBounty completed an underwritten public offering that resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Intrexon purchased $5,000 of additional AquaBounty common stock. In October 2018, certain investors exercised warrants acquired from the January 2018 offering, resulting in additional net proceeds of $4,316 , including $3,077 from Intrexon. Components of Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows: September 30, December 31, Unrealized gain (loss) on investments $ 20 $ (61 ) Loss on foreign currency translation adjustments (33,122 ) (28,551 ) Total accumulated other comprehensive loss $ (33,102 ) $ (28,612 )

Share-Based Payments

Share-Based Payments	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Payments	Share-Based Payments The Company measures the fair value of stock options and restricted stock units ("RSUs") issued to employees and nonemployees as of the grant date for the recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Cost of products $ 4 $ 14 $ 16 $ 64 Cost of services 52 51 169 207 Research and development 1,838 1,681 5,565 7,315 Selling, general and administrative 3,529 6,386 8,788 20,754 Total $ 5,423 $ 8,132 $ 14,538 $ 28,340 Intrexon Stock Option Plans In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors granted share-based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of September 30, 2019 , there were 380,930 stock options outstanding under the 2008 Plan. Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share-based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of September 30, 2019 , there were 25,000,000 shares authorized for issuance under the 2013 Plan, of which 9,149,553 stock options and 2,108,509 RSUs were outstanding and 8,496,486 shares were available for grant. In April 2019, Intrexon adopted the Intrexon Corporation 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of September 30, 2019 , there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which 4,513,060 were available for grant. Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 11,093,063 $ 27.95 6.81 Granted 1,536,075 6.53 Exercised (19,887 ) (3.17 ) Forfeited (824,192 ) (29.81 ) Expired (2,254,576 ) (39.05 ) Balances at September 30, 2019 9,530,483 21.77 6.68 Exercisable at September 30, 2019 6,306,218 24.97 5.81 RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 970,341 $ 13.82 1.43 Granted 2,278,460 6.59 Vested (927,880 ) (9.25 ) Forfeited (212,412 ) (9.20 ) Balances at September 30, 2019 2,108,509 8.48 1.33 Intrexon currently uses authorized and unissued shares to satisfy share award exercises. The Company's Chief Executive Officer ("CEO") receives a base salary of $200 per month payable in fully-vested shares of Intrexon common stock with such shares subject to a three -year lock-up on resale. The monthly number of shares of common stock was calculated based on the closing price on the last trading day of each month and the shares were issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement, which is subject to renewal annually by the compensation committee of the board of directors of the Company, expired March 31, 2019. In April 2019, the Company entered into a new RSU agreement with its CEO through March 31, 2020. Under the new RSU agreement, the base salary and lock-up terms remained unchanged from the original RSU Agreement. However, the number of fully-vested shares of Intrexon common stock paid monthly will be calculated based on the volume weighted average of the price of Intrexon common stock over the 30 day period ending on the last calendar day of each month. The fair value of the shares issued as compensation for services is included in selling, general and administrative expenses in the Company's consolidated statements of operations and totaled $444 and $499 for the three months ended September 30, 2019 and 2018 , respectively, and $1,425 and $1,468 for the nine months ended September 30, 2019 and 2018 , respectively.

Operating Leases

Operating Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Operating Leases	Operating Leases The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. The Company's leases have remaining terms of one to twenty years , some of which may include options to extend the lease and some of which may include options to terminate the lease within one year . The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions. The Company's finance leases are not material. The components of lease costs were as follows: Three Months Ended Nine Months Ended 2019 2019 Operating lease costs $ 2,665 $ 7,713 Short-term and variable lease costs 1,196 3,364 Lease costs $ 3,861 $ 11,077 As of September 30, 2019 , maturities of lease liabilities, excluding short-term leases, were as follows: 2019 $ 2,213 2020 11,456 2021 9,864 2022 8,920 2023 7,232 2024 7,102 Thereafter 26,691 Total 73,478 Present value adjustment (29,072 ) Total $ 44,406 Current portion of operating lease liabilities $ 6,224 Long-term portion of operating lease liabilities 38,182 Total $ 44,406 Other information related to operating leases was as follows: Nine Months Ended 2019 Supplemental Cash Flows Information Cash paid for operating lease liabilities $ 8,489 Operating lease right-of-use assets added in exchange for new lease liabilities 3,249 September 30, Weighted average remaining lease term (years) 8.63 Weighted average discount rate 11.59 % At December 31, 2018 , future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year were as follows: 2019 $ 9,182 2020 9,910 2021 9,127 2022 8,305 2023 7,229 Thereafter 34,157 Total $ 77,910

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments As of September 30, 2019 , the Company had outstanding contractual purchase commitments of $12,068 , which primarily relate to amounts to be paid in 2019, 2020, and 2021 upon delivery of commercial non-browning apple trees. Contingencies In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's sale of semen-sorting products and services breached a 2004 licensing agreement and infringed on patents related to semen sorting that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. The matter proceeded to a jury trial in the United States District Court for the District of Colorado in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial order, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with the ability to continue to practice XY's technology, subject to an ongoing royalty obligation of 12.5% of gross proceeds on Trans Ova's standard sorted semen products, plus a 2% enhancement on those products utilizing "reverse-sorted semen", or semen that is frozen before being sorted. In addition, the court assigned a $5.00 minimum royalty for a straw of sexed semen. Both parties appealed the district court's order. In May 2018, the Court of Appeals for the Federal Circuit denied Trans Ova's appeal of its claims for antitrust, breach of contract, and patent invalidity (except as to one patent, for which the Federal Circuit affirmed invalidity in a separate, same-day ruling in a third-party case). The Federal Circuit remanded the district court's calculation of the ongoing royalty and instructed the district court to re-calculate the ongoing royalty in light of post-verdict economic factors. In March 2019, the district court clarified the royalty base and reset the royalty rates consistent with the Federal Circuit's opinion. The district court increased the royalty rate on Trans Ova's standard sorted semen products to 18.75% . For the reverse-sort enhancement, however, it applied a weighted, blended royalty of 12.63% to Trans Ova's entire in vitro fertilization service cycle that utilizes reverse-sorted semen. The district court also changed the minimum royalty for a straw of sexed semen to $6.25 for a 2-million cell straw (prorated appropriately for straws of higher cell counts), and assigned a minimum royalty for a sexed embryo at $6.25 per embryo. The new royalty rates were made retroactive to February 2016 (the end date of the trial). Since the inception of the 2004 licensing agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the district court's April 2016 post-trial order and its March 2019 post-remand order, and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the 2004 agreement through the district court's April 2016 order, aggregate royalty and license payments were $3,170 , of which $2,759 had not yet been deposited by XY. In 2016, the Company recorded the expense of $4,228 , representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the district court's registry, to be held until the appeals process was complete and final judgment amounts were determined. These amounts were included in restricted cash and other accrued liabilities on the consolidated balance sheet as of December 31, 2018. After the appeal, the district court subsequently released the funds held in its registry to XY in January 2019. As for post-trial damages, Trans Ova continued to remit payment to XY every quarter based on the original ongoing royalty rates set by the district court, though XY refused to cash those checks. Under the district court's March 2019 post-remand order clarifying the royalty base and resetting the royalty rates, Trans Ova recalculated royalties owed from February 2016 through the first quarter of 2019, plus any applicable pre- and post-judgment interest, and remitted that payment, totaling $5,801 , to XY in May 2019. In June 2019, XY deposited the $5,801 into the district court's registry while the parties resolve a dispute over the appropriate calculation of royalties. In that dispute, which is pending before the district court, XY filed a motion claiming over $1,000 in additional back royalties. Trans Ova contends that no additional back royalties are due and is seeking an oral hearing on the matter. During the nine months ended September 30, 2019 , the Company recorded additional royalty expense of $383 based on the recalculation of royalties owed XY from February 2016 through December 2018. This amount is included in selling, general and administrative expenses on the accompanying consolidated statement of operations. In December 2016, XY filed a complaint for patent infringement, trade secret misappropriation, and various state law claims against Trans Ova in the United States District Court for the Western District of Texas in Waco, Texas. Since the claims in the 2016 complaint directly relate to the parties' other litigation, Trans Ova filed and was granted a motion to transfer the case to Colorado district court. That court subsequently dismissed nine of the complaint's twelve counts, including all five non-patent counts. The court subsequently dismissed another patent count after ruling that the patent was invalid, leaving only two patent counts left in the case. In February 2019, a Wisconsin district court invalidated one of the remaining patents, which XY had asserted against another competitor. That ruling prompted the Colorado district court to stay the two remaining patent counts and enter final judgment against XY's ten other dismissed counts. The 2016 litigation is administratively closed, pending XY's appeal of the district court's rulings dismissing its various patent and non-patent causes of action. Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation. The Company may become subject to other claims, assessments, and governmental investigations from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of September 30, 2019 , the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's CEO and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. In November 2015, the independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. The Services Agreement provides for a term of one year , can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's board of directors. The independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2020. Under the Services Agreement, as consideration for providing these services, Third Security is entitled to a fee paid in the form of fully-vested shares of Intrexon common stock that approximates $800 per month. Through 2018, the number of shares of common stock was calculated based on the closing price of the Company's common stock on the 15th day of each month and issued to Third Security at the end of the month. Beginning in 2019, the number of shares of common stock is calculated based on the volume weighted average of the closing price of the Company's common stock over the 30-day period ending on the 15th day of the calendar month when the applicable services are provided. Through May 2019, the payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan. Following the effectiveness of the 2019 Plan in June 2019, subsequent payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2019 Plan and are subject to the terms of the 2019 Plan (Note 14 ). For the three months ended September 30, 2019 and 2018 , the Company issued 340,453 shares and 166,143 shares, respectively, with values of $1,855 and $2,417 , respectively, to Third Security as payment for services pursuant to the Services Agreement. For the nine months ended September 30, 2019 and 2018 , the Company issued 1,180,446 shares and 466,460 shares, respectively, with values of $6,217 and $6,522 , respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement were $8 and $16 for the three months ended September 30, 2019 and 2018 , respectively, and $26 and $33 for the nine months ended September 30, 2019 and 2018 , respectively. See also Note 14 regarding compensation arrangements between the Company and its CEO. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $22 for the three months ended September 30, 2019 and 2018 , and $66 for the nine months ended September 30, 2019 and 2018 . Transactions with ECC Parties In addition to entities controlled by Third Security, entities in which the Company holds more than a de minimis equity interest, including equity securities received as upfront or milestone consideration, and that also are party to a collaboration with the Company, are considered to be related parties. In June 2016, the Company received 100,000 shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM Oncology, Inc. ("ZIOPHARM"), with a per share stated value of $1,200 , as consideration for amending their two previously existing ECC agreements. The Company received a monthly dividend, paid in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares. In conjunction with the reacquisition of certain rights previously licensed to ZIOPHARM in October 2018, the Company returned to ZIOPHARM all of the Preferred Shares owned or accrued by the Company as of the effective date of the agreement. During the three and nine months ended September 30, 2018 , the Company received an additional 3,847 and 11,205 Preferred Shares, respectively, and recognized $4,649 and $14,539 of dividend income in the accompanying consolidated statement of operations, respectively. Following the transaction in October 2018, ZIOPHARM is no longer considered a related party. In March 2017, Fibrocell sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), convertible into shares of Fibrocell common stock, and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $1,161 in exchange for 1,161 Convertible Preferred Shares and warrants to acquire 99,769 shares of Fibrocell common stock. The Convertible Preferred Shares are convertible at any time at the election of the Company and accrue dividends at 4% per annum, compounded quarterly, increasing the stated value of the shares. The investment in Fibrocell preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Convertible Preferred Shares are not traded on a public exchange. The fair value of the investment in Fibrocell preferred stock is estimated using a conversion plus dividend approach utilizing the trading value of the underlying common stock and an estimated premium for the preferred stock dividend and other preferences. Market price volatility of Fibrocell's common stock and a significant change in the estimated preferred stock premium could result in a significant impact to the fair value of the investment in Fibrocell preferred stock. As of September 30, 2019 and December 31, 2018 , the fair value of the Company's investment in Fibrocell preferred stock totaled $390 and $191 , respectively, and is included in other assets on the accompanying consolidated balance sheets. The Company also holds a promissory note convertible into shares of Fibrocell common stock ("convertible note") and additional warrants to purchase shares of Fibrocell common stock. As of September 30, 2019 and December 31, 2018 , the value of the convertible note and warrants totaled $253 and $120 , respectively, and is included in other assets on the accompanying consolidated balance sheets. In November 2017, concurrent with Oragenics closing a preferred stock private placement, the Company exchanged a promissory note, including accrued interest, purchased from Oragenics in May 2017 and receivables due from Oragenics totaling $3,385 for Oragenics Series C preferred stock ("Series C Preferred Stock"). The Series C Preferred Stock is non-voting and non-convertible and is redeemable in whole or part at any time by Oragenics in cash. The Series C Preferred Stock accrued an annual 12% dividend payable in additional Series C Preferred Stock through May 10, 2019, and after such date, the annual dividend increased to 20% . As of September 30, 2019 and December 31, 2018 , based on the most recent financial information available on Oragenics, the Company concluded that there was no value to its investment in Oragenics preferred stock. During 2018, the Company mutually terminated each of its ECC agreements with Histogenics Corporation, OvaScience, Inc., and Synthetic Biologics, Inc. Upon termination of these ECCs, the Company recognized the remaining deferred revenue totaling $11,877 , including $3,183 during the nine months ended September 30, 2018 .

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share The following table presents the computation of basic and diluted net loss per share: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Historical net loss per share: Numerator: Net loss attributable to Intrexon $ (53,634 ) $ (57,324 ) $ (153,109 ) $ (168,871 ) Denominator: Weighted average shares outstanding, basic and diluted 154,596,257 129,518,989 153,770,785 128,843,991 Net loss attributable to Intrexon per share, basic and diluted $ (0.35 ) $ (0.44 ) $ (1.00 ) $ (1.31 ) The following potentially dilutive securities as of September 30, 2019 and 2018 , have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months then ended as they would have been anti-dilutive: September 30, 2019 2018 Convertible debt 21,055,805 13,507,746 Options 9,530,483 11,160,524 Restricted stock units 2,108,509 980,758 Warrants 133,264 133,264 Total 32,828,061 25,782,292

Segments Segments

Segments Segments	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segments	Segments Through March 31, 2019, the Company was a single operating segment. In April 2019, the Company initiated efforts to better deploy resources, realize inherent synergies, and position the Company for growth with a core focus on healthcare and initiated plans to achieve this through various corporate activities, including partnering, potential asset sales, and operating cost reductions. Thereafter, the Company's CODM assessed the operating performance of and allocated resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) equity in net loss of affiliates, and (vii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's CODM now regularly reviews disaggregated financial information for each of the Company's operating segments. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to the newly identified reportable segments. For the three and nine months ended September 30, 2019 , the Company's reportable segments are (i) Precigen, (ii) MBP, (iii) the Fine Chemicals division, (iv) Okanagan, and (v) Trans Ova. These identified reportable segments met the quantitative thresholds for the nine months ended September 30, 2019 , to be reported separately. See Note 1 for a description of Precigen, MBP, Okanagan, and Trans Ova. The Company's Fine Chemicals division is an operating division within Intrexon which is focused primarily on microbial production of therapeutic compounds. The All Other category as reported below reflects Intrexon's other operating segments that do not meet the quantitative thresholds to report separately. Information by reportable segment was as follows: Three Months Ended September 30, 2019 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 444 $ 1,117 $ 2,177 $ 6 $ 13,981 $ 5,318 $ 23,043 Intersegment revenues 2,313 — 1,225 — 257 78 3,873 Total revenues $ 2,757 $ 1,117 $ 3,402 $ 6 $ 14,238 $ 5,396 $ 26,916 Segment Adjusted EBITDA $ (5,953 ) $ (9,024 ) $ 144 $ (4,323 ) $ (5,560 ) $ (8,526 ) $ (33,242 ) Three Months Ended September 30, 2018 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 6,822 $ 2,083 $ 1,103 $ 10 $ 15,634 $ 6,771 $ 32,423 Intersegment revenues 200 2 1,160 — 136 120 1,618 Total revenues $ 7,022 $ 2,085 $ 2,263 $ 10 $ 15,770 $ 6,891 $ 34,041 Segment Adjusted EBITDA $ (7,965 ) $ (8,192 ) $ (343 ) $ (5,158 ) $ (1,844 ) $ (9,054 ) $ (32,556 ) Nine Months Ended September 30, 2019 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 2,174 $ 3,813 $ 4,167 $ 45 $ 53,307 $ 18,711 $ 82,217 Intersegment revenues 7,090 2 4,090 — 1,204 646 13,032 Total revenues $ 9,264 $ 3,815 $ 8,257 $ 45 $ 54,511 $ 19,357 $ 95,249 Segment Adjusted EBITDA $ (20,789 ) $ (26,238 ) $ (979 ) $ (25,367 ) $ (2,854 ) $ (26,020 ) $ (102,247 ) Nine Months Ended September 30, 2018 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 22,285 $ 5,030 $ 4,211 $ 37 $ 59,467 $ 26,228 $ 117,258 Intersegment revenues 431 8 3,954 — 382 847 5,622 Total revenues $ 22,716 $ 5,038 $ 8,165 $ 37 $ 59,849 $ 27,075 $ 122,880 Segment Adjusted EBITDA $ (20,797 ) $ (22,059 ) $ (1,244 ) $ (16,609 ) $ (1,901 ) $ (31,088 ) $ (93,698 ) The table below reconciles total revenues from reportable segments to total consolidated revenues: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Total revenues from reportable segments $ 21,520 $ 27,150 $ 75,892 $ 95,805 Other revenues, including from other operating segments 5,396 6,916 19,504 27,497 Elimination of intersegment revenues (3,873 ) (1,618 ) (13,032 ) (5,913 ) Total consolidated revenues $ 23,043 $ 32,448 $ 82,364 $ 117,389 The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Segment Adjusted EBITDA for reportable segments $ (24,716 ) $ (23,502 ) $ (76,227 ) $ (62,610 ) All Other Segment Adjusted EBITDA (8,526 ) (9,054 ) (26,020 ) (31,088 ) Remove cash paid for capital expenditures and investments in affiliates 8,115 10,373 34,021 30,422 Add recognition of previously deferred revenue associated with upfront and milestone payments 5,770 7,201 16,685 24,100 Other expenses: Interest expense (4,471 ) (3,999 ) (13,140 ) (4,240 ) Depreciation and amortization (6,021 ) (8,303 ) (18,711 ) (25,184 ) Impairment loss (626 ) — (626 ) — Reacquisition of in-process research and development — (8,721 ) — (8,721 ) Stock-based compensation expense (5,423 ) (8,132 ) (14,538 ) (28,340 ) Equity in net loss of affiliates (1,647 ) (2,870 ) (5,034 ) (9,880 ) Other 35 — 35 — Unallocated corporate costs (13,544 ) (25,440 ) (43,657 ) (75,319 ) Eliminations (3,092 ) (621 ) (9,104 ) (1,659 ) Consolidated net loss before income taxes $ (54,146 ) $ (73,068 ) $ (156,316 ) $ (192,519 ) As of September 30, 2019 and December 31, 2018 , the Company had $14,373 and $16,839 , respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $3,325 and $2,235 for the three months ended September 30, 2019 and 2018 , respectively, and $7,785 and $10,389 for the nine months ended September 30, 2019 and 2018 , respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In October 2019, the independent members of the Company's board of directors, with the recommendation of the audit committee and an independent special committee of the Board, unanimously approved the sale of the Company's common shares held in AquaBounty to an affiliate of Third Security for $21,587 , resulting in a gain of $5,267 in the fourth quarter. As a result of this transaction, the Company classified its investment in AquaBounty as a current asset on the accompanying consolidated balance sheet as of September 30, 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of September 30, 2019 and results of operations and cash flows for the interim periods ended September 30, 2019 and 2018 . The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2019 , or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 .
Consolidation	The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Equity Securities	Equity Securities The Company holds equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluates whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statements of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represents cost and any adjustments for impairment or observable price changes in certain transactions. As of September 30, 2019 , there have been no adjustments for impairment or observable price changes for the Company's investments in private companies accounted for under the measurement alternative method. Equity securities that the Company does not intend to sell within one year are classified as noncurrent in the consolidated balance sheets. For equity securities received pursuant to a collaboration agreement, the Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.
Equity Method Investments	Equity Method Investments
Operating Leases	Operating Leases The Company adopted Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"), effective January 1, 2019. Under ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, with an ROU Asset of the same amount. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Segment Information	Segment Information The Company realigned its business in April 2019, and as a result, its chief operating decision maker ("CODM") now regularly reviews disaggregated financial information for various operating segments. The Company's reportable segments now include (i) Precigen; (ii) MBP; (iii) the Fine Chemicals division, which is an operating division of Intrexon; (iv) Okanagan; and (v) Trans Ova. All of Intrexon's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of Precigen, MBP, Okanagan, and Trans Ova. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to multiple reportable segments. See Note 19 for further discussion of the Company's segments.
Recently Issued and Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company adopted ASC 842 on January 1, 2019 using the modified retrospective method as of the adoption date without restating prior periods. In addition, the Company elected to use the package of practical expedients which allowed the Company to not have to reassess whether expired or existing contracts contain leases under the new definition of a lease or the lease classification for expired or existing leases under ASC Topic 840. As a result of the adoption of ASC 842, the Company recorded ROU Assets and lease liabilities of approximately $43,500 and $45,500 , respectively, as of January 1, 2019. The difference between the ROU Assets and lease liabilities primarily represents the balance of deferred rent as of December 31, 2018 that resulted from historical straight-lining of operating leases expense, which was reclassified upon adoption to reduce the measurement of the ROU Assets. There was no impact to accumulated deficit. In June 2018, the FASB issued Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The provisions of ASU 2018-07 expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this standard effective January 1, 2019, and there was no material impact to the accompanying consolidated financial statements. Recently Issued Accounting Pronouncements In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified or removed. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, but entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. This standard is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13") . The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). The provisions of ASU 2019-04 clarify and improve areas of guidance related to ASU 2016-13 and ASC Topic 825, Financial Instruments ("ASC 825"). The amendments to ASU 2016-13 have the same effective date as the original ASU and are effective for the Company for the year ending December 31, 2020. The amendments to ASC 825 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted, and are effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summarized Financial Information for the Equity Method Investments	Summarized financial data as of September 30, 2019 and December 31, 2018 and for the three and nine months ended September 30, 2019 and 2018 , for the Company's equity method investments are shown in the following tables. September 30, December 31, Current assets $ 16,983 $ 17,485 Noncurrent assets 59,231 31,274 Total assets 76,214 48,759 Current liabilities 6,788 4,226 Noncurrent liabilities 4,766 — Total liabilities 11,554 4,226 Net assets $ 64,660 $ 44,533 Three Months Ended Nine Months Ended 2019 2018 2019 2018 Revenues $ 206 $ 113 $ 601 $ 353 Operating expenses 6,843 11,621 21,604 30,762 Operating loss (6,637 ) (11,508 ) (21,003 ) (30,409 ) Other, net 1 12 9 33 Net loss $ (6,636 ) $ (11,496 ) $ (20,994 ) $ (30,376 )

Collaboration and Licensing R_2

Collaboration and Licensing Revenue (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summarized Collaboration and Licensing Revenues	The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2019 and 2018 . Three Months Ended Nine Months Ended 2019 2018 2019 2018 ZIOPHARM Oncology, Inc. $ 431 $ 4,826 $ 2,130 $ 13,626 Ares Trading S.A. — 1,576 — 7,525 Oragenics, Inc. 231 705 615 867 Intrexon T1D Partners, LLC — 368 — 2,399 Intrexon Energy Partners, LLC 823 1,329 2,596 3,345 Intrexon Energy Partners II, LLC 293 754 1,217 1,685 Surterra Holdings, Inc. 1,022 — 1,182 — Genopaver, LLC 494 689 1,186 3,076 Fibrocell Science, Inc. 402 391 3,247 1,015 Persea Bio, LLC 1,083 199 621 714 Harvest start-up entities (1) 100 2,691 4,862 11,792 Other 1,306 796 3,596 5,578 Total $ 6,185 $ 14,324 $ 21,252 $ 51,622 (1) For the three and nine months ended September 30, 2019 and 2018 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the nine months ended September 30, 2018 , revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.
Summary of Deferred Revenue	Deferred revenue consists of the following: September 30, December 31, Collaboration and licensing agreements $ 74,431 $ 63,284 Prepaid product and service revenues 3,054 2,933 Other 1,639 3,547 Total $ 79,124 $ 69,764 Current portion of deferred revenue $ 12,764 $ 15,554 Long-term portion of deferred revenue 66,360 54,210 Total $ 79,124 $ 69,764
Summary of Deferred Revenue by Collaborator	The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2019 and December 31, 2018 , including the estimated remaining performance period as of September 30, 2019 . Average Remaining Performance Period (Years) September 30, December 31, ZIOPHARM Oncology, Inc. 0.0 $ — $ 1,214 Oragenics, Inc. 4.7 5,463 5,810 Intrexon Energy Partners, LLC 4.5 8,362 10,267 Intrexon Energy Partners II, LLC 5.2 12,843 14,060 Surterra Holdings, Inc. 8.7 13,987 — Genopaver, LLC 4.5 789 1,175 Fibrocell Science, Inc. 5.1 18,102 17,519 Persea Bio, LLC 5.3 3,553 2,697 Harvest start-up entities (1) 5.4 6,993 7,644 Other 1.7 4,297 2,898 Total $ 74,389 $ 63,284 (1) As of September 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments	The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of September 30, 2019 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 44,925 $ 20 $ — $ 44,945 Certificates of deposit 340 — — 340 Total $ 45,265 $ 20 $ — $ 45,285 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 119,401 $ — $ (61 ) $ 119,340 Certificates of deposit 348 — — 348 Total $ 119,749 $ — $ (61 ) $ 119,688

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis	The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at September 30, 2019 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) September 30, Assets U.S. government debt securities $ — $ 44,945 $ — $ 44,945 Equity securities 1,687 298 16,320 18,305 Other — 593 390 983 Total $ 1,687 $ 45,836 $ 16,710 $ 64,233 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2018 : Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 119,340 $ — $ 119,340 Equity securities 1,626 556 — 2,182 Other — 468 191 659 Total $ 1,626 $ 120,364 $ 191 $ 122,181
Schedule of Changes in Level 3 Investments	The following table summarizes the changes in the Level 3 investments in equity securities and preferred stock during the nine months ended September 30, 2019 . Nine Months Ended Beginning balance $ 191 Retained interest in deconsolidated subsidiary 14,239 Dividend income from investments in preferred stock 38 Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock 2,242 Ending balance $ 16,710

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: September 30, December 31, Supplies, embryos and other production materials $ 3,461 $ 4,729 Work in process 4,656 4,391 Livestock 6,505 10,167 Feed 2,673 2,160 Total inventory $ 17,295 $ 21,447

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following: September 30, December 31, Land and land improvements $ 11,011 $ 12,490 Buildings and building improvements 11,607 20,371 Furniture and fixtures 1,388 1,891 Equipment 67,020 74,555 Leasehold improvements 30,722 28,289 Breeding stock 4,867 4,582 Computer hardware and software 11,385 11,697 Trees 16,728 11,910 Construction and other assets in progress 26,319 18,880 181,047 184,665 Less: Accumulated depreciation and amortization (58,341 ) (55,791 ) Property, plant and equipment, net $ 122,706 $ 128,874

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2019 are as follows: Balance at December 31, 2018 $ 149,585 Impairment (178 ) Foreign currency translation adjustments (1,458 ) Balance at September 30, 2019 $ 147,949
Schedule of Intangible Assets	Intangible assets consist of the following as of September 30, 2019 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 136,114 $ (38,804 ) $ 97,310 Customer relationships 10,700 (8,221 ) 2,479 Trademarks 5,900 (3,685 ) 2,215 In-process research and development 5,137 — 5,137 Total $ 157,851 $ (50,710 ) $ 107,141 Intangible assets consist of the following as of December 31, 2018 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 152,482 $ (35,133 ) $ 117,349 Customer relationships 10,700 (7,565 ) 3,135 Trademarks 6,800 (3,341 ) 3,459 In-process research and development 5,348 — 5,348 Total $ 175,330 $ (46,039 ) $ 129,291

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Long-Term Debt Instruments	Long-term debt consists of the following: September 30, December 31, Convertible debt $ 211,037 $ 203,391 Notes payable 4,204 4,551 Other 226 3,852 Long-term debt 215,467 211,794 Less current portion 31,433 559 Long-term debt, less current portion $ 184,034 $ 211,235
Schedule of Components of Interest Expense	The components of interest expense related to the Convertible Notes were as follows: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Cash interest expense $ 1,750 $ 1,731 $ 5,250 $ 1,731 Non-cash interest expense 2,430 2,116 6,962 2,116 Total interest expense $ 4,180 $ 3,847 $ 12,212 $ 3,847
Schedule of Future Maturities of Long-Term Debt	Future maturities of long-term debt are as follows: 2019 $ 127 2020 31,487 2021 25,330 2022 340 2023 200,354 2024 367 Thereafter 2,399 Total $ 260,404

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss are as follows: September 30, December 31, Unrealized gain (loss) on investments $ 20 $ (61 ) Loss on foreign currency translation adjustments (33,122 ) (28,551 ) Total accumulated other comprehensive loss $ (33,102 ) $ (28,612 )

Share-Based Payments (Tables)

Share-Based Payments (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Costs	Stock-based compensation costs included in the consolidated statements of operations are presented below: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Cost of products $ 4 $ 14 $ 16 $ 64 Cost of services 52 51 169 207 Research and development 1,838 1,681 5,565 7,315 Selling, general and administrative 3,529 6,386 8,788 20,754 Total $ 5,423 $ 8,132 $ 14,538 $ 28,340
Schedule of Stock Option Activity	Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 11,093,063 $ 27.95 6.81 Granted 1,536,075 6.53 Exercised (19,887 ) (3.17 ) Forfeited (824,192 ) (29.81 ) Expired (2,254,576 ) (39.05 ) Balances at September 30, 2019 9,530,483 21.77 6.68 Exercisable at September 30, 2019 6,306,218 24.97 5.81
Schedule of Restricted Stock Unit Activity	RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 970,341 $ 13.82 1.43 Granted 2,278,460 6.59 Vested (927,880 ) (9.25 ) Forfeited (212,412 ) (9.20 ) Balances at September 30, 2019 2,108,509 8.48 1.33

Operating Leases (Tables)

Operating Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Components of Lease Costs	Other information related to operating leases was as follows: Nine Months Ended 2019 Supplemental Cash Flows Information Cash paid for operating lease liabilities $ 8,489 Operating lease right-of-use assets added in exchange for new lease liabilities 3,249 September 30, Weighted average remaining lease term (years) 8.63 Weighted average discount rate 11.59 % The components of lease costs were as follows: Three Months Ended Nine Months Ended 2019 2019 Operating lease costs $ 2,665 $ 7,713 Short-term and variable lease costs 1,196 3,364 Lease costs $ 3,861 $ 11,077
Maturities of Lease Liabilities	As of September 30, 2019 , maturities of lease liabilities, excluding short-term leases, were as follows: 2019 $ 2,213 2020 11,456 2021 9,864 2022 8,920 2023 7,232 2024 7,102 Thereafter 26,691 Total 73,478 Present value adjustment (29,072 ) Total $ 44,406 Current portion of operating lease liabilities $ 6,224 Long-term portion of operating lease liabilities 38,182 Total $ 44,406
Future Minimum Lease Payments	At December 31, 2018 , future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year were as follows: 2019 $ 9,182 2020 9,910 2021 9,127 2022 8,305 2023 7,229 Thereafter 34,157 Total $ 77,910

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss per Share	The following table presents the computation of basic and diluted net loss per share: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Historical net loss per share: Numerator: Net loss attributable to Intrexon $ (53,634 ) $ (57,324 ) $ (153,109 ) $ (168,871 ) Denominator: Weighted average shares outstanding, basic and diluted 154,596,257 129,518,989 153,770,785 128,843,991 Net loss attributable to Intrexon per share, basic and diluted $ (0.35 ) $ (0.44 ) $ (1.00 ) $ (1.31 )
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share	The following potentially dilutive securities as of September 30, 2019 and 2018 , have been excluded from the above computations of diluted weighted average shares outstanding for the three and nine months then ended as they would have been anti-dilutive: September 30, 2019 2018 Convertible debt 21,055,805 13,507,746 Options 9,530,483 11,160,524 Restricted stock units 2,108,509 980,758 Warrants 133,264 133,264 Total 32,828,061 25,782,292

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Information by Reportable Segment	Information by reportable segment was as follows: Three Months Ended September 30, 2019 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 444 $ 1,117 $ 2,177 $ 6 $ 13,981 $ 5,318 $ 23,043 Intersegment revenues 2,313 — 1,225 — 257 78 3,873 Total revenues $ 2,757 $ 1,117 $ 3,402 $ 6 $ 14,238 $ 5,396 $ 26,916 Segment Adjusted EBITDA $ (5,953 ) $ (9,024 ) $ 144 $ (4,323 ) $ (5,560 ) $ (8,526 ) $ (33,242 ) Three Months Ended September 30, 2018 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 6,822 $ 2,083 $ 1,103 $ 10 $ 15,634 $ 6,771 $ 32,423 Intersegment revenues 200 2 1,160 — 136 120 1,618 Total revenues $ 7,022 $ 2,085 $ 2,263 $ 10 $ 15,770 $ 6,891 $ 34,041 Segment Adjusted EBITDA $ (7,965 ) $ (8,192 ) $ (343 ) $ (5,158 ) $ (1,844 ) $ (9,054 ) $ (32,556 ) Nine Months Ended September 30, 2019 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 2,174 $ 3,813 $ 4,167 $ 45 $ 53,307 $ 18,711 $ 82,217 Intersegment revenues 7,090 2 4,090 — 1,204 646 13,032 Total revenues $ 9,264 $ 3,815 $ 8,257 $ 45 $ 54,511 $ 19,357 $ 95,249 Segment Adjusted EBITDA $ (20,789 ) $ (26,238 ) $ (979 ) $ (25,367 ) $ (2,854 ) $ (26,020 ) $ (102,247 ) Nine Months Ended September 30, 2018 Precigen MBP Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 22,285 $ 5,030 $ 4,211 $ 37 $ 59,467 $ 26,228 $ 117,258 Intersegment revenues 431 8 3,954 — 382 847 5,622 Total revenues $ 22,716 $ 5,038 $ 8,165 $ 37 $ 59,849 $ 27,075 $ 122,880 Segment Adjusted EBITDA $ (20,797 ) $ (22,059 ) $ (1,244 ) $ (16,609 ) $ (1,901 ) $ (31,088 ) $ (93,698 )
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The table below reconciles total revenues from reportable segments to total consolidated revenues: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Total revenues from reportable segments $ 21,520 $ 27,150 $ 75,892 $ 95,805 Other revenues, including from other operating segments 5,396 6,916 19,504 27,497 Elimination of intersegment revenues (3,873 ) (1,618 ) (13,032 ) (5,913 ) Total consolidated revenues $ 23,043 $ 32,448 $ 82,364 $ 117,389 The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Segment Adjusted EBITDA for reportable segments $ (24,716 ) $ (23,502 ) $ (76,227 ) $ (62,610 ) All Other Segment Adjusted EBITDA (8,526 ) (9,054 ) (26,020 ) (31,088 ) Remove cash paid for capital expenditures and investments in affiliates 8,115 10,373 34,021 30,422 Add recognition of previously deferred revenue associated with upfront and milestone payments 5,770 7,201 16,685 24,100 Other expenses: Interest expense (4,471 ) (3,999 ) (13,140 ) (4,240 ) Depreciation and amortization (6,021 ) (8,303 ) (18,711 ) (25,184 ) Impairment loss (626 ) — (626 ) — Reacquisition of in-process research and development — (8,721 ) — (8,721 ) Stock-based compensation expense (5,423 ) (8,132 ) (14,538 ) (28,340 ) Equity in net loss of affiliates (1,647 ) (2,870 ) (5,034 ) (9,880 ) Other 35 — 35 — Unallocated corporate costs (13,544 ) (25,440 ) (43,657 ) (75,319 ) Eliminations (3,092 ) (621 ) (9,104 ) (1,659 ) Consolidated net loss before income taxes $ (54,146 ) $ (73,068 ) $ (156,316 ) $ (192,519 )

Organization (Details)

Organization (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Noncontrolling Interest [Line Items]
Loss on deconsolidation of subsidiary	$ 2,648
Net assets divested from deconsolidation	$ 38,682
AquaBounty Technologies, Inc.
Noncontrolling Interest [Line Items]
Ownership interest	38.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Liquidity and Going Concern - Additional Information (Details) $ in Thousands	Sep. 30, 2019USD ($)
Accounting Policies [Abstract]
Cash, cash equivalents, and short-term investments	$ 89,713

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
AquaBounty Technologies, Inc.
Schedule of Equity Method Investments [Line Items]
Equity method investments, fair value disclosure	$ 16,320		$ 16,320
Ownership interest	38.00%		38.00%
Unrealized appreciation (depreciation) in fair value of equity securities	$ (3,721)		$ 2,081
Oragenics, Inc.
Schedule of Equity Method Investments [Line Items]
Unrealized appreciation (depreciation) in fair value of equity securities		$ (387)		$ (1,547)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summarized Financial Information for the Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Operating expenses	$ 71,660	$ 98,919	$ 227,093	$ 286,117
Operating loss	(48,617)	(66,471)	(144,729)	(168,728)
Other, net	(3,882)	(3,727)	(6,553)	(13,911)
Equity Method Investments
Schedule of Equity Method Investments [Line Items]
Current assets	16,983		16,983		$ 17,485
Noncurrent assets	59,231		59,231		31,274
Total assets	76,214		76,214		48,759
Current liabilities	6,788		6,788		4,226
Noncurrent liabilities	4,766		4,766		0
Total liabilities	11,554		11,554		4,226
Net assets	64,660		64,660		$ 44,533
Revenues	206	113	601	353
Operating expenses	6,843	11,621	21,604	30,762
Operating loss	(6,637)	(11,508)	(21,003)	(30,409)
Other, net	1	12	9	33
Net loss	$ (6,636)	$ (11,496)	$ (20,994)	$ (30,376)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Maximum risk of loss related to the identified VIEs	$ 20,453	$ 21,219

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Segment Information (Details)	3 Months Ended
	Mar. 31, 2019segment
Accounting Policies [Abstract]
Number of reportable segments	1,000

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets	$ 43,211		$ 0
Operating lease liabilities	$ 44,406
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets		$ 43,500
Operating lease liabilities		$ 45,500

Mergers and Acquisitions - Asse

Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Aug. 31, 2018
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition		$ 0	$ 30,000,000
Cash received in asset acquisition		0	15,500,000
Investments in affiliates		17,487,000		$ 18,859,000
Deferred revenue		79,124,000		$ 69,764,000
Write-off of in-process research and development acquired in asset acquisition		$ 0	8,721,000
CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc.
Business Acquisition [Line Items]
Investments in affiliates					$ 4,303,000
Ownership interest		100.00%
Deferred revenue	$ 10,078,000		$ 10,078,000
Write-off of in-process research and development acquired in asset acquisition	8,721,000
Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Cash received in asset acquisition	15,500,000
ActoBio Therapeutics Inc. | Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition	$ 30,000,000

Investments in Joint Ventures -

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended
	Mar. 31, 2014USD ($)	Sep. 30, 2019USD ($)board_seat	Dec. 31, 2018USD ($)
Schedule of Equity Method Investments [Line Items]
Investment		$ 17,487,000	$ 18,859,000
Intrexon Energy Partners, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Maximum additional capital contribution committed	$ 25,000,000
Additional capital contributions committed, remaining commitment		$ 4,225,000
Total number of seats on the joint venture's governing board | board_seat		5
Total number of seats on the joint venture's governing board, internally selected | board_seat		2
Total number of seats on the joint venture's governing board, externally selected | board_seat		3
Intrexon Energy Partners, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment		$ (355,000)	$ (656,000)
Intrexon Energy Partners, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Capital contributions	$ 25,000,000
Maximum additional capital contribution committed	25,000,000
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 25,000,000

Investments in Joint Ventures_2

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015USD ($)board_seat	Sep. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Schedule of Equity Method Investments [Line Items]
Investment		$ 17,487,000	$ 18,859,000
Intrexon Energy Partners II, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Maximum additional capital contribution committed	$ 10,000,000
Total number of seats on the joint venture's governing board | board_seat	5
Total number of seats on the joint venture's governing board, internally selected | board_seat	1
Total number of seats on the joint venture's governing board, externally selected | board_seat	4
Intrexon Energy Partners II, LLC | Other Accrued Liabilities
Schedule of Equity Method Investments [Line Items]
Investment		$ (425,000)	$ (50,000)
Intrexon Energy Partners II, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Capital contributions	$ 18,000,000
Maximum additional capital contribution committed	10,000,000
Intrexon Energy Partners II, LLC | All Investors
Schedule of Equity Method Investments [Line Items]
Capital contributions	4,000,000
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value	$ 18,000,000

Investments in Joint Ventures_3

Investments in Joint Ventures - EnviroFlight - Additional Information (Details) - USD ($) $ in Thousands	43 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Investment	$ 17,487	$ 18,859
EnviroFlight, LLC
Schedule of Equity Method Investments [Line Items]
Capital contributions	19,000
EnviroFlight, LLC | Investments In Affiliates
Schedule of Equity Method Investments [Line Items]
Investment	15,629	$ 16,720
Investors | EnviroFlight, LLC
Schedule of Equity Method Investments [Line Items]
Capital contributions	$ 19,000

Investments in Joint Ventures_4

Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)	1 Months Ended		9 Months Ended
	Nov. 30, 2018USD ($)shares	Mar. 31, 2016USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Oct. 31, 2018board_seat
Schedule of Equity Method Investments [Line Items]
Deferred revenue			$ 79,124,000		$ 69,764,000
Write-off of in-process research and development acquired in asset acquisition			0	$ 8,721,000
Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Deferred revenue			$ 74,431,000		$ 63,284,000
Intrexon T1D Partners, LLC
Schedule of Equity Method Investments [Line Items]
Ownership interest	100.00%	50.00%
Maximum additional capital contribution committed		$ 5,000,000
Total number of seats on the joint venture's governing board, internally selected | board_seat						2
Total number of seats on the joint venture's governing board, externally selected | board_seat						3
Stock issued during period, shares, purchase of assets (in shares) | shares	1,933,737
Stock issued during period, value, purchase of assets	$ 18,970,000
Deferred revenue	8,517,000
Write-off of in-process research and development acquired in asset acquisition	$ 10,453,000
Intrexon T1D Partners, LLC | Investors
Schedule of Equity Method Investments [Line Items]
Ownership interest		50.00%
Capital contributions		$ 10,000,000
Maximum additional capital contribution committed		5,000,000
Intrexon T1D Partners, LLC | Collaboration and licensing agreements
Schedule of Equity Method Investments [Line Items]
Collaborative arrangement consideration received, value		$ 10,000,000

Collaboration and Licensing R_3

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		$ 23,043	$ 32,448	$ 82,364	$ 117,389
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		6,185	14,324	21,252	51,622
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		431	4,826	2,130	13,626
Ares Trading S.A. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		0	1,576	0	7,525
Oragenics, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		231	705	615	867
Intrexon T1D Partners, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		0	368	0	2,399
Intrexon Energy Partners, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		823	1,329	2,596	3,345
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		293	754	1,217	1,685
Surterra Holdings, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		1,022	0	1,182	0
Genopaver, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		494	689	1,186	3,076
Fibrocell Science, Inc. | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		402	391	3,247	1,015
Persea Bio, LLC | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		1,083	199	621	714
Harvest start-up entities | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	[1]	100	2,691	4,862	11,792
Other | Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		$ 1,306	$ 796	$ 3,596	$ 5,578
[1]	For the three and nine months ended September 30, 2019 and 2018 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the nine months ended September 30, 2018 , revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.

Collaboration and Licensing R_4

Collaboration and Licensing Revenue - Surterra Collaboration (Details) - Surterra Holdings, Inc. $ in Thousands	1 Months Ended
	Jun. 30, 2019USD ($)
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement consideration received, cash	$ 10,000
Collaborative arrangement consideration received, value	$ 4,530
Collaboration agreement termination notice period	90 days
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments required upon successful achievement	$ 68,000

Collaboration and Licensing R_5

Collaboration and Licensing Revenue - Fibrocell Science Collaboration (Details) - Fibrocell Science, Inc. - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2019	Sep. 30, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement, percentage of sublicensing income	50.00%
Collaboration and licensing agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement consideration received, cash		$ 3,750

Collaboration and Licensing R_6

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 79,124	$ 69,764
Current portion of deferred revenue	12,764	15,554
Long-term portion of deferred revenue	66,360	54,210
Collaboration and licensing agreements
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	74,431	63,284
Prepaid product and service revenues
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	3,054	2,933
Other
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	$ 1,639	$ 3,547

Collaboration and Licensing R_7

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($) $ in Thousands		Sep. 30, 2019	Dec. 31, 2018
Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			$ 63,284
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 74,389
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			1,214
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		0 years
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 0
Oragenics, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			5,810
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 8 months 12 days
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 5,463
Intrexon Energy Partners, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			10,267
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 6 months
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 8,362
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			14,060
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		5 years 2 months 12 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 12,843
Surterra Holdings, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			0
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		8 years 8 months 12 days
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 13,987
Genopaver, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			1,175
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		4 years 6 months
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 789
Fibrocell Science, Inc. | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			17,519
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		5 years 1 month 6 days
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 18,102
Persea Bio, LLC | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			2,697
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		5 years 3 months 18 days
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 3,553
Harvest start-up entities | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	[1]		7,644
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)	[1]	5 years 4 months 24 days
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue	[1]	$ 6,993
Other | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue			$ 2,898
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01
Contract With Customer, Asset And Liability [Line Items]
Average remaining performance period (in years)		1 year 8 months 12 days
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-10-01 | Upfront and Milestone Payments
Contract With Customer, Asset And Liability [Line Items]
Deferred revenue		$ 4,297
[1]	As of September 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Collaboration and Licensing R_8

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details) - Upfront and Milestone Payments $ in Thousands	Dec. 31, 2018USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 63,284
ZIOPHARM Oncology, Inc.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	1,214
Oragenics, Inc.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	5,810
Intrexon Energy Partners, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	10,267
Intrexon Energy Partners II, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	14,060
Surterra Holdings, Inc.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	0
Genopaver, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	1,175
Fibrocell Science, Inc.
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	17,519
Persea Bio, LLC
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	2,697
Harvest start-up entities
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	7,644	[1]
Other
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Deferred revenue	$ 2,898
[1]	As of September 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

Short-term Investments - Summar

Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 45,265	$ 119,749
Gross Unrealized Gains	20	0
Gross Unrealized Losses	0	(61)
Aggregate Fair Value	45,285	119,688
U.S. government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	44,925	119,401
Gross Unrealized Gains	20	0
Gross Unrealized Losses	0	(61)
Aggregate Fair Value	44,945	119,340
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	340	348
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 340	$ 348

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 64,233	$ 122,181
Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	1,687	1,626
Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	45,836	120,364
Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	16,710	191
U.S. government debt securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	44,945	119,340
U.S. government debt securities | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
U.S. government debt securities | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	44,945	119,340
U.S. government debt securities | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Equity securities
Assets
Fair value of financial assets measured at fair value on a recurring basis	18,305	2,182
Equity securities | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	1,687	1,626
Equity securities | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	298	556
Equity securities | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	16,320	0
Other
Assets
Fair value of financial assets measured at fair value on a recurring basis	983	659
Other | Quoted Prices in Active Markets (Level 1)
Assets
Fair value of financial assets measured at fair value on a recurring basis	0	0
Other | Significant Other Observable Inputs (Level 2)
Assets
Fair value of financial assets measured at fair value on a recurring basis	593	468
Other | Significant Unobservable Inputs (Level 3)
Assets
Fair value of financial assets measured at fair value on a recurring basis	$ 390	$ 191

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Changes in Level 3 Investments (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Dividend income from investments in preferred stock	$ 38	$ 14,575
Significant Unobservable Inputs (Level 3)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	191
Retained interest in deconsolidated subsidiary	14,239
Dividend income from investments in preferred stock	38
Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock	2,242
Ending balance	$ 16,710

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Jul. 31, 2018
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liabilities measured at fair value on a recurring basis	$ 585,000	$ 585,000
Changes in fair value of Level 3 liabilities	$ 0
3.5% Convertible Notes Due 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, interest rate, stated percentage	3.50%		3.50%
Fair value of convertible debt	$ 122,000,000	141,000,000
Carrying value of convertible debt	$ 155,063,000	$ 148,101,000	$ 143,723,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory [Line Items]
Inventory	$ 17,295	$ 21,447
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	3,461	4,729
Work in process
Inventory [Line Items]
Inventory	4,656	4,391
Livestock
Inventory [Line Items]
Inventory	6,505	10,167
Feed
Inventory [Line Items]
Inventory	$ 2,673	$ 2,160

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 11,011	$ 12,490
Buildings and building improvements	11,607	20,371
Furniture and fixtures	1,388	1,891
Equipment	67,020	74,555
Leasehold improvements	30,722	28,289
Breeding stock	4,867	4,582
Computer hardware and software	11,385	11,697
Trees	16,728	11,910
Construction and other assets in progress	26,319	18,880
Property, plant and equipment, gross	181,047	184,665
Less: Accumulated depreciation and amortization	(58,341)	(55,791)
Property, plant and equipment, net	$ 122,706	$ 128,874

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)reporting_unit	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Property, Plant and Equipment [Abstract]
Property, plant and equipment divested from deconsolidation	$ 24,186		$ 24,186
Property, plant and equipment, impairment loss	$ 448		448
Number of reporting units closed | reporting_unit	2
Loss on disposal		$ 85		$ 5,057
Depreciation expense	$ 3,293	$ 3,614	$ 10,213	$ 10,712

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Goodwill
Beginning balance		$ 149,585
Impairment	$ (178)	(178)
Foreign currency translation adjustments		(1,458)
Ending balance	$ 147,949	$ 147,949

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)reporting_unit	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill accumulated impairment losses	$ 14,001		$ 14,001		$ 13,823
Goodwill, impairment loss	178		178
Intangible assets divested from deconsolidation	11,567		11,567
Amortization expense	$ 2,728	$ 4,689	$ 8,498	$ 14,472
Number of reporting units closed | reporting_unit	2

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	$ (50,710)	$ (46,039)
Intangible Assets
Gross Carrying Amount	157,851	175,330
Net	107,141	129,291
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	136,114	152,482
Accumulated Amortization	(38,804)	(35,133)
Net	97,310	117,349
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	10,700	10,700
Accumulated Amortization	(8,221)	(7,565)
Net	2,479	3,135
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	5,900	6,800
Accumulated Amortization	(3,685)	(3,341)
Net	2,215	3,459
In-process research and development
Finite-Lived Intangible Assets, Net [Abstract]
In-process research and development	$ 5,137	$ 5,348

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit	9 Months Ended
	Sep. 30, 2019USD ($)
Trans Ova Genetics, LC | First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 8,000,000
Line of credit facility, interest rate at period end	5.06%
Line of credit facility, outstanding balance	$ 0
Line of credit facility, current borrowing capacity	$ 7,930,000
Trans Ova Genetics, LC | First National Bank of Omaha | Minimum
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%
Trans Ova Genetics, LC | First National Bank of Omaha | London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Line of credit facility, basis spread on variable rate	2.95%
Exemplar Genetics, LLC | American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	5.75%
Line of credit facility, outstanding balance	$ 569,000

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Schedule of Long-Term Debt Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long-term debt	$ 215,467	$ 211,794
Less current portion	31,433	559
Long-term debt, less current portion	184,034	211,235
Convertible debt
Debt Instrument [Line Items]
Long-term debt	211,037	203,391
Notes payable
Debt Instrument [Line Items]
Long-term debt	4,204	4,551
Other
Debt Instrument [Line Items]
Long-term debt	$ 226	$ 3,852

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended			3 Months Ended		9 Months Ended
	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 31, 2018USD ($)day$ / shares	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Debt Instrument [Line Items]
Long-term debt divested from deconsolidation				$ 4,030,000		$ 4,030,000
Proceeds from long-term debt, net of issuance costs						376,000	$ 194,000,000
Equity component of convertible debt, net of issuance costs and deferred taxes					$ 36,868,000		36,868,000
Deferred income taxes				467,000	14,246,000	1,448,000	19,335,000
Accrued interest				1,750,000		1,750,000
Long-term debt issued to a related party in an asset acquisition						0	30,000,000
Interest expense				4,471,000	$ 3,999,000	13,140,000	$ 4,240,000
Long-term debt	$ 211,794,000			215,467,000		215,467,000
Convertible debt
Debt Instrument [Line Items]
Long-term debt	203,391,000			211,037,000		211,037,000
Notes payable
Debt Instrument [Line Items]
Long-term debt	4,551,000			4,204,000		4,204,000
ActoBio Therapeutics Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.00%			3.00%		3.00%
Interest expense				232,000	$ 60,000	684,000	$ 60,000
Long-term debt				$ 30,974,000		$ 30,974,000
Trans Ova Genetics, LC | Notes payable | American State Bank
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				3.95%		3.95%
Long-term debt				$ 4,180,000		$ 4,180,000
Debt instrument, periodic payment						39,000
Harvest Intrexon Enterprise Fund I, LP | ActoBio Therapeutics Inc.
Debt Instrument [Line Items]
Long-term debt issued to a related party in an asset acquisition		$ 30,000,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount			$ 200,000,000	$ 200,000,000		$ 200,000,000
Proceeds from long-term debt, net of issuance costs			193,958,000
Debt issuance costs			$ 6,042,000
Debt instrument, interest rate, stated percentage			3.50%	3.50%		3.50%
Conversion rate			58.6622
Principal amount used in conversion			$ 1,000
Conversion price (in usd per share) | $ / shares			$ 17.05
Debt instrument redemption price, percentage			100.00%
Carrying value of convertible debt	148,101,000		$ 143,723,000	$ 155,063,000		$ 155,063,000
Equity component of convertible debt, net of issuance costs and deferred taxes			50,235,000
Deferred income taxes			$ 13,367,000		$ 13,367,000
Effective interest rate on convertible notes				11.02%		11.02%
Convertible notes, unamortized discount and issuance costs				$ 44,937,000		$ 44,937,000
3.5% Convertible Notes Due 2023 | Minimum
Debt Instrument [Line Items]
Common stock price trading days | day			20
Common stock price consecutive trading days | day			30
Percentage of common share price over conversion price for conversion			130.00%
3.5% Convertible Notes Due 2023 | Maximum
Debt Instrument [Line Items]
Common stock price trading days | day			5
Common stock price consecutive trading days | day			5
Debt instrument redemption price, percentage			98.00%
Merck Convertible Note
Debt Instrument [Line Items]
Aggregate principal amount	$ 25,000,000
Conversion rate upon IPO	0.90
Interest rate applicable to IPO conversion event	0.05

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Schedule of Components of Interest Expense (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Debt Instrument [Line Items]
Cash interest expense	$ 1,750	$ 1,731	$ 5,250	$ 1,731
Non-cash interest expense	2,430	2,116	6,962	2,116
Total interest expense	$ 4,180	$ 3,847	$ 12,212	$ 3,847

Lines of Credit and Long-Term_7

Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands	Sep. 30, 2019USD ($)
Debt Disclosure [Abstract]
2019	$ 127
2020	31,487
2021	25,330
2022	340
2023	200,354
2024	367
Thereafter	2,399
Total	$ 260,404

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating Loss Carryforwards [Line Items]
Deferred income tax benefit		$ 467	$ 14,246	$ 1,448	$ 19,335
Deferred tax liabilities		5,732		5,732
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Taxable loss		47,100	39,100	194,400	104,400
Current income tax expense (benefit)			(31)		82
Operating and capital loss carryforwards		564,100		564,100
Research and development tax credits		9,200		9,200
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Current income tax expense (benefit)		(45)	(45)	(167)	$ (282)
Operating loss carryforwards		159,200		159,200
Generated After 2017
Operating Loss Carryforwards [Line Items]
Operating and capital loss carryforwards		$ 311,400		$ 311,400
3.5% Convertible Notes Due 2023
Operating Loss Carryforwards [Line Items]
Deferred income tax benefit	$ 13,367		$ 13,367

Shareholders' Equity - Issuance

Shareholders' Equity - Issuances of Intrexon Common Stock (Details) $ in Thousands	1 Months Ended
	Jan. 31, 2018USD ($)shares
Class of Stock [Line Items]
Shares issued (in shares) | shares	6,900,000
Net proceeds from public financing	$ 82,374
Underwriting discounts and commissions	3,688
Capitalized offering expenses	$ 188
Affiliate of Third Security, LLC
Class of Stock [Line Items]
Shares issued (in shares) | shares	1,000,000

Shareholders' Equity - Share Le

Shareholders' Equity - Share Lending Agreement (Details) - $ / shares	1 Months Ended	9 Months Ended
	Jul. 31, 2018	Sep. 30, 2018
Equity [Abstract]
Borrowed shares, number issued (in shares)	7,479,431	7,479,431
Borrowed shares, public offering price per share (in usd per share)	$ 13.37

Shareholders' Equity - Issuan_2

Shareholders' Equity - Issuances of AquaBounty Common Stock (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended
	Mar. 31, 2019	Oct. 31, 2018	Jan. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Class of Stock [Line Items]
Shares and warrants issued in public offerings, net of issuance costs						$ 6,611	$ 87,990
Net proceeds from exercises of warrants				$ 6	$ 141	$ 313	$ 1,074
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Shares and warrants issued in public offerings, net of issuance costs	$ 6,611		$ 10,616
Net proceeds from exercises of warrants		$ 4,316
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Consolidation, less than wholly owned subsidiary, parent ownership interest, changes, purchase of interest by parent		$ 3,077	$ 5,000

Shareholders' Equity - Componen

Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ 228,421	$ 362,855
Unrealized gain (loss) on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	20	(61)
Loss on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	(33,122)	(28,551)
Total accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ (33,102)	$ (28,612)

Share-Based Payments - Schedule

Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ 5,423	$ 8,132	$ 14,538	$ 28,340
Cost of products
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	4	14	16	64
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	52	51	169	207
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	1,838	1,681	5,565	7,315
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation costs	$ 3,529	$ 6,386	$ 8,788	$ 20,754

Share-Based Payments - Addition

Share-Based Payments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services			$ 7,987	$ 8,404
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly compensation, in the form of equity			$ 200
Lock-up period			3 years
Chief Executive Officer | Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services	$ 444	$ 499	$ 1,425	$ 1,468
Intrexon Stock Option Plan - 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)					0
Options outstanding (in shares)	380,930		380,930
Intrexon Stock Option Plan - 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	8,496,486		8,496,486
Options outstanding (in shares)	9,149,553		9,149,553
Number of shares authorized for issuance (in shares)	25,000,000		25,000,000
RSUs outstanding (in shares)	2,108,509		2,108,509
Intrexon Stock Option Plan - 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	4,513,060		4,513,060
Number of shares authorized for issuance (in shares)	5,000,000		5,000,000

Share-Based Payments - Schedu_2

Share-Based Payments - Schedule of Stock Option Activity (Details) - Intrexon Stock Option Plans - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Number of Shares
Balances at beginning of period (in shares)	11,093,063
Granted (in shares)	1,536,075
Exercised (in shares)	(19,887)
Forfeited (in shares)	(824,192)
Expired (in shares)	(2,254,576)
Balances at end of period (in shares)	9,530,483	11,093,063
Exercisable at end of period (in shares)	6,306,218
Weighted Average Exercise Price
Balances at beginning of period (in usd per share)	$ 27.95
Granted (in usd per share)	6.53
Exercised (in usd per share)	(3.17)
Forfeited (in usd per share)	(29.81)
Expired (in usd per share)	(39.05)
Balances at period end (in usd per share)	21.77	$ 27.95
Exercisable, weighted average exercise price, at end of period (in usd per share)	$ 24.97
Weighted Average Remaining Contractual Term (Years)
Balances, weighted average remaining contractual period	6 years 8 months 4 days	6 years 9 months 21 days
Exercisable at period end, weighted average remaining contractual period	5 years 9 months 21 days

Share-Based Payments - Schedu_3

Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Number of Restricted Stock Units
Forfeited (in shares)	(212,412)
Weighted Average Grant Date Fair Value
Forfeited (in usd per share)	$ (9.20)
Intrexon Stock Option Plans
Number of Restricted Stock Units
Balances at beginning of period (in shares)	970,341
Granted (in shares)	2,278,460
Vested (in shares)	(927,880)
Balances at end of period (in shares)	2,108,509	970,341
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 13.82
Granted (in usd per share)	6.59
Vested (in usd per share)	(9.25)
Balances at end of period (in usd per share)	$ 8.48	$ 13.82
Additional Information
Weighted Average Remaining Contractual Term (Years)	1 year 3 months 29 days	1 year 5 months 4 days

Operating Leases - Additional I

Operating Leases - Additional Information (Details)	9 Months Ended
	Sep. 30, 2019
Lessee, Lease, Description [Line Items]
Termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Term of contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of contract	20 years

Operating Leases - Components o

Operating Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating lease costs	$ 2,665	$ 7,713
Short-term and variable lease costs	1,196	3,364
Lease costs	$ 3,861	$ 11,077

Operating Leases - Maturities o

Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2019	$ 2,213
2020	11,456
2021	9,864
2022	8,920
2023	7,232
2024	7,102
Thereafter	26,691
Total	73,478
Present value adjustment	(29,072)
Total	44,406
Current portion of lease liabilities	6,224	$ 0
Long-term portion of operating lease liabilities	$ 38,182	$ 0

Operating Leases - Other Inform

Operating Leases - Other Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Supplemental Cash Flows Information
Cash paid for operating lease liabilities	$ 8,489
Operating lease right-of-use assets added in exchange for new lease liabilities	$ 3,249

Operating Leases - Lease Terms

Operating Leases - Lease Terms and Discount Rates (Details)	Sep. 30, 2019
Leases [Abstract]
Weighted average remaining lease term (years)	8 years 7 months 17 days
Weighted average discount rate	11.59%

Operating Leases - Future Minim

Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]
2019	$ 9,182
2020	9,910
2021	9,127
2022	8,305
2023	7,229
Thereafter	34,157
Total	$ 77,910

Commitments and Contingencies -

Commitments and Contingencies - Purchase Commitments - Additional Information (Details) $ in Thousands	Sep. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Outstanding contractual purchase commitments	$ 12,068

Commitments and Contingencies_2

Commitments and Contingencies - Contingencies - Additional Information (Details) - Licensing and patent infringement suit	1 Months Ended		9 Months Ended	12 Months Ended	38 Months Ended	148 Months Ended
	Mar. 31, 2019	Apr. 30, 2016USD ($)	Sep. 30, 2019USD ($)claim	Dec. 31, 2016USD ($)	Mar. 31, 2019USD ($)	Apr. 30, 2016USD ($)	Feb. 28, 2019claim
Loss Contingencies [Line Items]
Damages awarded to Trans Ova		$ 528,000
Back royalties			$ 1,000,000
Litigation settlement, aggregate royalty and license payment					$ 5,801,000	$ 3,170,000
Royalty payments not yet deposited		2,759,000				$ 2,759,000
Litigation settlement expense				$ 4,228,000
Royalty expense			$ 383,000
XY, LLC
Loss Contingencies [Line Items]
Damages awarded against Trans Ova		$ 6,066,000
Litigation settlement, ongoing royalty percentage		12.50%	18.75%
Enhancement rate on products utilizing reverse sorting		2.00%
Cumulative payments for royalties and licenses		$ 5	$ 6.25
Weighted blended royalty rate	12.63%
Claims dismissed | claim			9
Total claims | claim			12
Non-Patent Counts, Number | claim			5
Claims pending resolution | claim			2				1

Related Party Transactions - A

Related Party Transactions - Additional Information (Details) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Nov. 30, 2015	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Related Party Transaction [Line Items]
Shares issued as payment for services					$ 2,299,000	$ 2,917,000	$ 7,987,000	$ 8,404,000
Noncash dividend income							38,000	14,575,000
Fair value of financial assets measured at fair value on a recurring basis					64,233,000		64,233,000		$ 122,181,000
Revenues					23,043,000	32,448,000	82,364,000	117,389,000
Third Security, LLC
Related Party Transaction [Line Items]
Initial term of services agreement				1 year
Expense for services					$ 8,000	$ 16,000	$ 26,000	$ 33,000
Shares issued as payment for services (in shares)					340,453	166,143	1,180,446	466,460
Shares issued as payment for services					$ 1,855,000	$ 2,417,000	$ 6,217,000	$ 6,522,000
Sublease rental income					$ 22,000		$ 66,000	66,000
Third Security, LLC | Common Stock
Related Party Transaction [Line Items]
Expense for services				$ 800,000
Histogenics Corporation, OvaScience Inc., and Synthetic Biologics Inc.
Related Party Transaction [Line Items]
Revenues								$ 3,183,000	11,877,000
Third Security, LLC | Chief Executive Officer
Related Party Transaction [Line Items]
Ownership interest					100.00%		100.00%
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Preferred shares, stated value (in usd per share)			$ 1,200
Preferred shares, dividend rate (in usd per share)			$ 12
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Convertible preferred shares issued (in shares)		1,161
Warrants, number of common shares into which warrants can be converted (in shares)		99,769
Convertible preferred shares, dividend rate		4.00%
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Collaborative arrangement consideration received, number of preferred shares (in shares)			100,000
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Purchases of preferred stock and warrants		$ 1,161,000
Fibrocell Science, Inc. | Preferred stock | Other Noncurrent Assets
Related Party Transaction [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					$ 390,000		$ 390,000		191,000
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Dividend income, number of preferred shares received (in shares)						3,847		11,205
Noncash dividend income						$ 4,649,000		$ 14,539,000
Convertible Note and Warrants | Other Noncurrent Assets | Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					253,000		253,000		120,000
Oragenics, Inc. | Preferred stock
Related Party Transaction [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					$ 0		$ 0		$ 0
Receivables converted to preferred stock	$ 3,385,000
Preferred shares, initial dividend rate							12.00%
Preferred shares, subsequent dividend rate							20.00%

Net Loss per Share - Computatio

Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Numerator:
Net loss attributable to Intrexon	$ (53,634)	$ (57,324)	$ (153,109)	$ (168,871)
Denominator:
Weighted average shares outstanding, basic and diluted (in shares)	154,596,257	129,518,989	153,770,785	128,843,991
Net loss attributable to Intrexon per share, basic and diluted (in usd per share)	$ (0.35)	$ (0.44)	$ (1)	$ (1.31)

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	32,828,061	25,782,292	32,828,061	25,782,292
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	21,055,805	13,507,746	21,055,805	13,507,746
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	9,530,483	11,160,524	9,530,483	11,160,524
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	2,108,509	980,758	2,108,509	980,758
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	133,264	133,264	133,264	133,264

Segments - Information by Repor

Segments - Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Revenues from external customers	$ 23,043	$ 32,448	$ 82,364	$ 117,389
Segment Adjusted EBITDA	(33,242)	(32,556)	(102,247)	(93,698)
Precigen
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(5,953)	(7,965)	(20,789)	(20,797)
MBP
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(9,024)	(8,192)	(26,238)	(22,059)
Fine Chemicals
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	144	(343)	(979)	(1,244)
Okanagan
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(4,323)	(5,158)	(25,367)	(16,609)
Trans Ova
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(5,560)	(1,844)	(2,854)	(1,901)
All Other
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(8,526)	(9,054)	(26,020)	(31,088)
Operating segments
Segment Reporting Information [Line Items]
Revenues from external customers	23,043	32,423	82,217	117,258
Revenues	26,916	34,041	95,249	122,880
Operating segments | Precigen
Segment Reporting Information [Line Items]
Revenues from external customers	444	6,822	2,174	22,285
Revenues	2,757	7,022	9,264	22,716
Operating segments | MBP
Segment Reporting Information [Line Items]
Revenues from external customers	1,117	2,083	3,813	5,030
Revenues	1,117	2,085	3,815	5,038
Operating segments | Fine Chemicals
Segment Reporting Information [Line Items]
Revenues from external customers	2,177	1,103	4,167	4,211
Revenues	3,402	2,263	8,257	8,165
Operating segments | Okanagan
Segment Reporting Information [Line Items]
Revenues from external customers	6	10	45	37
Revenues	6	10	45	37
Operating segments | Trans Ova
Segment Reporting Information [Line Items]
Revenues from external customers	13,981	15,634	53,307	59,467
Revenues	14,238	15,770	54,511	59,849
Operating segments | All Other
Segment Reporting Information [Line Items]
Revenues from external customers	5,318	6,771	18,711	26,228
Revenues	5,396	6,891	19,357	27,075
Intersegment revenues
Segment Reporting Information [Line Items]
Revenues	3,873	1,618	13,032	5,622
Intersegment revenues | Precigen
Segment Reporting Information [Line Items]
Revenues	2,313	200	7,090	431
Intersegment revenues | MBP
Segment Reporting Information [Line Items]
Revenues	0	2	2	8
Intersegment revenues | Fine Chemicals
Segment Reporting Information [Line Items]
Revenues	1,225	1,160	4,090	3,954
Intersegment revenues | Okanagan
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Intersegment revenues | Trans Ova
Segment Reporting Information [Line Items]
Revenues	257	136	1,204	382
Intersegment revenues | All Other
Segment Reporting Information [Line Items]
Revenues	$ 78	$ 120	$ 646	$ 847

Segments - Reconciliation of Re

Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	$ 23,043	$ 32,448	$ 82,364	$ 117,389
Other revenues, including from other operating segments
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	5,396	6,916	19,504	27,497
Elimination of intersegment revenues
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	(3,873)	(1,618)	(13,032)	(5,913)
Total revenues from reportable segments
Segment Reporting, Asset Reconciling Item [Line Items]
Revenues	$ 21,520	$ 27,150	$ 75,892	$ 95,805

Segments - Reconciliation of Ne

Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	$ (33,242)	$ (32,556)	$ (102,247)	$ (93,698)
Other expenses:
Interest expense	(4,471)	(3,999)	(13,140)	(4,240)
Depreciation and amortization			(18,711)	(25,184)
Impairment loss	(626)	0	(626)	0
Stock-based compensation expense	(5,423)	(8,132)	(14,538)	(28,340)
Equity in net loss of affiliates	(1,647)	(2,870)	(5,034)	(9,880)
Other			(3,284)	(635)
Loss before income taxes	(54,146)	(73,068)	(156,316)	(192,519)
Operating segments
Segment Reporting Information [Line Items]
Remove cash paid for capital expenditures and investments in affiliates	8,115	10,373	34,021	30,422
Corporate And Reconciling Items
Other expenses:
Interest expense	(4,471)	(3,999)	(13,140)	(4,240)
Depreciation and amortization	(6,021)	(8,303)	(18,711)	(25,184)
Impairment loss	(626)	0	(626)	0
Reacquisition of in-process research and development	0	(8,721)	0	(8,721)
Stock-based compensation expense	(5,423)	(8,132)	(14,538)	(28,340)
Equity in net loss of affiliates	(1,647)	(2,870)	(5,034)	(9,880)
Other	35	0	35	0
Unallocated corporate costs
Other expenses:
Loss before income taxes	(13,544)	(25,440)	(43,657)	(75,319)
Eliminations
Other expenses:
Loss before income taxes	(3,092)	(621)	(9,104)	(1,659)
Reportable segments
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(24,716)	(23,502)	(76,227)	(62,610)
All Other
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(8,526)	(9,054)	(26,020)	(31,088)
Upfront and Milestone Payments | Operating segments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	$ 5,770	$ 7,201	$ 16,685	$ 24,100

Segments - Additional Informati

Segments - Additional Information (Details) - Non-US - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Long-lived assets	$ 14,373		$ 14,373		$ 16,839
Revenues	$ 3,325	$ 2,235	$ 7,785	$ 10,389

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Oct. 31, 2019	Dec. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Subsequent Event [Line Items]
Proceeds from sales of equity securities					$ 589	$ 217
Gain on equity securities			$ (3,068)	$ (7,287)	$ 2,634	$ (27,565)
AquaBounty Technologies, Inc. | Forecast
Subsequent Event [Line Items]
Gain on equity securities		$ 5,267
Affiliate of Third Security, LLC | AquaBounty Technologies, Inc. | Subsequent Event
Subsequent Event [Line Items]
Proceeds from sales of equity securities	$ 21,587